Immortalization	O
of	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
and	I-cell_type
CD8	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
by	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
Tax	B-protein
mutants	I-protein
expressed	O
in	O
a	O
functional	B-cell_line
molecular	I-cell_line
clone	I-cell_line
.	O

The	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HTLV-1	I-protein
)	I-protein
transcriptional	I-protein
trans-activator	I-protein
Tax	B-protein
has	O
been	O
demonstrated	O
to	O
have	O
transforming	O
activity	O
in	O
multiple	B-cell_line
cell	I-cell_line
culture	I-cell_line
and	O
transgenic-mouse	O
models	O
.	O

In	O
addition	O
to	O
activating	O
transcription	O
from	O
the	O
viral	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
through	O
the	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element	I-protein
binding	I-protein
protein/activating	I-protein
transcription	I-protein
factor	I-protein
(	I-protein
CREB/ATF	I-protein
)	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
,	O
Tax	B-protein
activates	O
the	O
expression	O
of	O
multiple	B-DNA
cellular	I-DNA
promoters	I-DNA
through	O
the	O
NF-kappaB	B-protein
pathway	O
of	O
transcriptional	O
activation	O
.	O

The	O
Tax	B-protein
mutants	I-protein
M22	B-protein
and	O
M47	B-protein
have	O
previously	O
been	O
demonstrated	O
to	O
selectively	O
abrogate	O
the	O
ability	O
of	O
Tax	B-protein
to	O
activate	O
transcription	O
through	O
the	O
NF-kappaB	O
or	O
CREB/ATF	O
pathway	O
,	O
respectively	O
.	O

These	O
mutations	O
were	O
introduced	O
in	O
the	O
tax	B-DNA
gene	I-DNA
of	O
the	O
ACH	B-DNA
functional	I-DNA
molecular	I-DNA
clone	I-DNA
of	O
HTLV-1	O
,	O
and	O
virus	O
produced	O
from	O
the	O
mutant	B-DNA
ACH	I-DNA
clones	I-DNA
was	O
examined	O
for	O
the	O
ability	O
to	O
replicate	O
and	O
immortalize	O
primary	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
.	O

While	O
virus	O
derived	O
from	O
the	O
clone	O
containing	O
the	O
M47	B-protein
mutation	O
retained	O
the	O
ability	O
to	O
immortalize	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
the	O
M22	B-protein
mutant	O
lost	O
the	O
ability	O
to	O
immortalize	O
infected	B-cell_type
cells	I-cell_type
.	O

These	O
results	O
indicate	O
that	O
activation	O
of	O
the	O
CREB/ATF	B-protein
pathway	O
by	O
Tax	B-protein
is	O
dispensable	O
for	O
the	O
immortalization	O
of	O
T	B-cell_type
cells	I-cell_type
by	O
HTLV-1	O
,	O
whereas	O
activation	O
of	O
the	O
NF-kappaB	B-protein
pathway	O
may	O
be	O
critical	O
.	O

JOURNAL	NULL
or	NULL
ViRoLOGY	NULL
,	NULL
June	NULL
1999	NULL
,	NULL
p.	NULL
4856-4865	NULL
0022-538	NULL
X/99/	NULL
$	NULL
04.00+0	NULL
Vol	NULL
.	NULL

73	NULL
,	NULL
No	NULL
.	NULL

6	NULL
Copyright	NULL
©	NULL
1999	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
.	NULL

All	NULL
Rights	NULL
Reserved	NULL
.	NULL

Immortalization	NULL
of	NULL
CD4*	NULL
and	NULL
CD8	NULL
*	NULL
T	NULL
Lymphocytes	NULL
by	NULL
Human	NULL
T-Cell	NULL
Leukemia	NULL
Virus	NULL
Type	NULL
1	NULL
Tax	NULL
Mutants	NULL
Expressed	NULL
in	NULL
a	NULL
Functional	NULL
Molecular	NULL
Clone	NULL
MICHAEL	NULL
D.	NULL
ROBEK	NULL
anp	NULL
LEE	NULL
RATNER*	NULL
Departments	NULL
of	NULL
Medicine	NULL
,	NULL
Pathology	NULL
,	NULL
and	NULL
Molecular	NULL
Microbiology	NULL
,	NULL
Washington	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
Missouri	NULL
63110	NULL
Received	NULL
25	NULL
November	NULL
1998/Accepted	NULL
8	NULL
March	NULL
1999	NULL
The	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HTLV-1	NULL
)	NULL
transcriptional	NULL
frans-activator	NULL
Tax	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
have	NULL
transforming	NULL
activity	NULL
in	NULL
multiple	NULL
cell	NULL
culture	NULL
and	NULL
transgenic-mouse	NULL
models	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
activating	NULL
transcription	NULL
from	NULL
the	NULL
viral	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
through	NULL
the	NULL
cyclic	NULL
AMP	NULL
response	NULL
element	NULL
binding	NULL
protein/activating	NULL
transcription	NULL
factor	NULL
(	NULL
CREB/ATF	NULL
)	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
,	NULL
Tax	NULL
activates	NULL
the	NULL
expression	NULL
of	NULL
multiple	NULL
cellular	NULL
promoters	NULL
through	NULL
the	NULL
NF-KB	NULL
pathway	NULL
of	NULL
transcriptional	NULL
activation	NULL
.	NULL

The	NULL
Tax	NULL
mutants	NULL
M22	NULL
and	NULL
M47	NULL
have	NULL
previously	NULL
been	NULL
demonstrated	NULL
to	NULL
selectively	NULL
abrogate	NULL
the	NULL
ability	NULL
of	NULL
Tax	NULL
to	NULL
activate	NULL
transcription	NULL
through	NULL
the	NULL
NF-B	NULL
or	NULL
CREB/ATF	NULL
pathway	NULL
,	NULL
respectively	NULL
.	NULL

These	NULL
mutations	NULL
were	NULL
introduced	NULL
in	NULL
the	NULL
tax	NULL
gene	NULL
of	NULL
the	NULL
ACH	NULL
functional	NULL
molecular	NULL
clone	NULL
of	NULL
HTLV-1	NULL
,	NULL
and	NULL
virus	NULL
produced	NULL
from	NULL
the	NULL
mutant	NULL
ACH	NULL
clones	NULL
was	NULL
examined	NULL
for	NULL
the	NULL
ability	NULL
to	NULL
replicate	NULL
and	NULL
immortalize	NULL
primary	NULL
human	NULL
lymphocytes	NULL
.	NULL

While	NULL
virus	NULL
derived	NULL
from	NULL
the	NULL
clone	NULL
containing	NULL
the	NULL
M47	NULL
mutation	NULL
retained	NULL
the	NULL
ability	NULL
to	NULL
immortalize	NULL
T	NULL
lymphocytes	NULL
,	NULL
the	NULL
M22	NULL
mutant	NULL
lost	NULL
the	NULL
ability	NULL
to	NULL
immortalize	NULL
infected	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
activation	NULL
of	NULL
the	NULL
CREB/ATF	NULL
pathway	NULL
by	NULL
Tax	NULL
is	NULL
dispensable	NULL
for	NULL
the	NULL
immortalization	NULL
of	NULL
T	NULL
cells	NULL
by	NULL
HTLV-1	NULL
,	NULL
whereas	NULL
activation	NULL
of	NULL
the	NULL
NF-KB	NULL
pathway	NULL
may	NULL
be	NULL
critical	NULL
.	NULL

The	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HTLV-1	NULL
)	NULL
infects	NULL
and	NULL
immortalizes	NULL
T	NULL
lymphocytes	NULL
in	NULL
vitro	NULL
and	NULL
is	NULL
the	NULL
causative	NULL
agent	NULL
of	NULL
adult	NULL
T-cell	NULL
leukemia/lymphoma	NULL
and	NULL
HTLV-1-asso-ciated	NULL
myelopathy/tropical	NULL
spastic	NULL
paraparesis	NULL
in	NULL
vivo	NULL
(	NULL
16	NULL
,	NULL
22	NULL
,	NULL
53	NULL
,	NULL
57	NULL
)	NULL
.	NULL

The	NULL
HTLV-1	NULL
genome	NULL
encodes	NULL
a	NULL
40-kDa	NULL
transcriptional	NULL
frans-activator	NULL
known	NULL
as	NULL
Tax	NULL
,	NULL
which	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
have	NULL
transforming	NULL
activity	NULL
(	NULL
2	NULL
,	NULL
17	NULL
,	NULL
43	NULL
,	NULL
63	NULL
,	NULL
70	NULL
,	NULL
78	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
activating	NULL
transcription	NULL
from	NULL
the	NULL
viral	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
(	NULL
10	NULL
,	NULL
13	NULL
,	NULL
27	NULL
,	NULL
66	NULL
)	NULL
,	NULL
Tax	NULL
activates	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
number	NULL
of	NULL
cellular	NULL
genes	NULL
,	NULL
many	NULL
of	NULL
which	NULL
either	NULL
encode	NULL
proteins	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
cellular	NULL
proliferation	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
interleukin	NULL
2	NULL
[	NULL
IL-2	NULL
]	NULL
[	NULL
68	NULL
]	NULL
,	NULL
IL-2	NULL
receptor	NULL
«	NULL
chain	NULL
[	NULL
3	NULL
,	NULL
25	NULL
,	NULL
40	NULL
,	NULL
68	NULL
]	NULL
,	NULL
and	NULL
proliferating	NULL
cell	NULL
nuclear	NULL
antigen	NULL
[	NULL
PCNA	NULL
]	NULL
[	NULL
58	NULL
]	NULL
)	NULL
or	NULL
are	NULL
proto-oncogenes	NULL
(	NULL
c-fos	NULL
[	NULL
14	NULL
]	NULL
and	NULL
c-sis	NULL
[	NULL
75	NULL
]	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
Tax	NULL
alters	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
number	NULL
of	NULL
cell	NULL
cycle	NULL
regulators	NULL
,	NULL
including	NULL
cyclin	NULL
D	NULL
(	NULL
49	NULL
)	NULL
,	NULL
the	NULL
mitotic	NULL
checkpoint	NULL
regulator	NULL
MAD1	NULL
(	NULL
30	NULL
)	NULL
,	NULL
the	NULL
cyclin-dependent	NULL
kinases	NULL
(	NULL
Cdk	NULL
)	NULL
Cdk4	NULL
and	NULL
Cdk6	NULL
(	NULL
65	NULL
)	NULL
,	NULL
the	NULL
Cdk	NULL
inhibitor	NULL
pl6INK4a	NULL
(	NULL
41	NULL
,	NULL
72	NULL
)	NULL
,	NULL
and	NULL
the	NULL
tumor	NULL
suppressor	NULL
p53	NULL
(	NULL
46	NULL
,	NULL
55	NULL
,	NULL
56	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
Tax	NULL
disregulates	NULL
the	NULL
cell	NULL
cycle	NULL
through	NULL
many	NULL
different	NULL
mechanisms	NULL
,	NULL
leading	NULL
to	NULL
the	NULL
eventual	NULL
immortalization	NULL
and	NULL
transformation	NULL
of	NULL
the	NULL
infected	NULL
cell	NULL
.	NULL

Tax	NULL
activates	NULL
transcription	NULL
through	NULL
a	NULL
number	NULL
of	NULL
different	NULL
transcription	NULL
factors	NULL
,	NULL
including	NULL
cyclic	NULL
AMP	NULL
response	NULL
element	NULL
binding	NULL
protein/activating	NULL
transcription	NULL
factor	NULL
(	NULL
CREB/ATF	NULL
)	NULL
(	NULL
4	NULL
,	NULL
7	NULL
,	NULL
8	NULL
,	NULL
74	NULL
,	NULL
80	NULL
)	NULL
,	NULL
NF-KB	NULL
(	NULL
3	NULL
,	NULL
15	NULL
,	NULL
24	NULL
,	NULL
32	NULL
,	NULL
44	NULL
)	NULL
,	NULL
p67	NULL
serum	NULL
response	NULL
factor	NULL
(	NULL
SRF	NULL
)	NULL
(	NULL
14	NULL
,	NULL
71	NULL
)	NULL
,	NULL
Sp1	NULL
(	NULL
75	NULL
)	NULL
,	NULL
and	NULL
NGFI-A/Egr-1	NULL
(	NULL
75	NULL
)	NULL
.	NULL

Tax	NULL
activates	NULL
transcription	NULL
through	NULL
the	NULL
CREB/ATF	NULL
pathway	NULL
by	NULL
at	NULL
least	NULL
two	NULL
distinct	NULL
mechanisms	NULL
.	NULL

First	NULL
,	NULL
Tax	NULL
binds	NULL
CREB1	NULL
and	NULL
increases	NULL
the	NULL
affinity	NULL
of	NULL
CREBI1	NULL
for	NULL
the	NULL
three	NULL
21-bp	NULL
repeats	NULL
in	NULL
the	NULL
HTLV-1	NULL
LTR	NULL
,	NULL
which	NULL
contain	NULL
nonconsensus	NULL
CREB	NULL
re	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Division	NULL
of	NULL
Molecular	NULL
Oncology	NULL
,	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Box	NULL
8069	NULL
,	NULL
660	NULL
South	NULL
Euclid	NULL
Ave.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
63110	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
314	NULL
)	NULL
362-8836	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
314	NULL
)	NULL
747-2797	NULL
.	NULL

E-mail	NULL
:	NULL
Iratner	NULL
@	NULL
imgate.wustl.edu	NULL
.	NULL

4856	NULL
sponse	NULL
elements	NULL
and	NULL
are	NULL
involved	NULL
in	NULL
Tax-activated	NULL
and	NULL
basal	NULL
expression	NULL
of	NULL
the	NULL
LTR	NULL
(	NULL
1	NULL
,	NULL
5	NULL
,	NULL
39	NULL
,	NULL
80	NULL
,	NULL
81	NULL
)	NULL
.	NULL

Second	NULL
,	NULL
Tax	NULL
interacts	NULL
with	NULL
the	NULL
CREB	NULL
transcriptional	NULL
coactivators	NULL
CREB-binding	NULL
protein	NULL
(	NULL
CBP	NULL
)	NULL
and	NULL
p300	NULL
,	NULL
thereby	NULL
recruiting	NULL
them	NULL
to	NULL
the	NULL
CREB-Tax-21-bp	NULL
repeat	NULL
complex	NULL
(	NULL
6	NULL
,	NULL
20	NULL
,	NULL
37	NULL
)	NULL
.	NULL

Likewise	NULL
,	NULL
Tax	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
interact	NULL
with	NULL
various	NULL
members	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
family	NULL
and	NULL
their	NULL
inhibitors	NULL
,	NULL
including	NULL
p50	NULL
,	NULL
p100	NULL
,	NULL
and	NULL
p105	NULL
(	NULL
23	NULL
,	NULL
47	NULL
,	NULL
64	NULL
)	NULL
.	NULL

Recent	NULL
evidence	NULL
suggests	NULL
that	NULL
Tax	NULL
also	NULL
increases	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
by	NULL
increasing	NULL
the	NULL
activity	NULL
of	NULL
mitogen-activated	NULL
protein/extracellular	NULL
signal-related	NULL
kinase	NULL
kinase	NULL
1	NULL
(	NULL
MEKK1	NULL
)	NULL
and	NULL
NF-	NULL
«	NULL
kB-inducing	NULL
kinase	NULL
(	NULL
NIK	NULL
)	NULL
,	NULL
which	NULL
phosphorylate	NULL
and	NULL
activate	NULL
the	NULL
IxB	NULL
kinases	NULL
IKK	NULL
and	NULL
IKKf	NULL
(	NULL
15	NULL
,	NULL
79	NULL
)	NULL
.	NULL

The	NULL
IKK	NULL
kinases	NULL
then	NULL
phosphorylate	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
inhibitors	NULL
IxBa	NULL
and	NULL
IxBB	NULL
,	NULL
leading	NULL
to	NULL
IxB	NULL
degradation	NULL
and	NULL
nuclear	NULL
translocation	NULL
of	NULL
the	NULL
active	NULL
NF-	NULL
«	NULL
B	NULL
subunits	NULL
(	NULL
44	NULL
,	NULL
45	NULL
)	NULL
.	NULL

A	NULL
number	NULL
of	NULL
mutations	NULL
in	NULL
Tax	NULL
have	NULL
been	NULL
described	NULL
which	NULL
selectively	NULL
abrogate	NULL
the	NULL
ability	NULL
of	NULL
Tax	NULL
to	NULL
upregulate	NULL
transcription	NULL
through	NULL
the	NULL
CREB/ATF	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
transcriptional	NULL
activation	NULL
pathways	NULL
(	NULL
67	NULL
,	NULL
69	NULL
,	NULL
78	NULL
)	NULL
.	NULL

Two	NULL
of	NULL
these	NULL
mutations	NULL
,	NULL
termed	NULL
M22	NULL
and	NULL
M47	NULL
,	NULL
have	NULL
been	NULL
extensively	NULL
characterized	NULL
and	NULL
were	NULL
chosen	NULL
for	NULL
examination	NULL
in	NULL
this	NULL
study	NULL
(	NULL
69	NULL
)	NULL
.	NULL

The	NULL
M22	NULL
mutation	NULL
is	NULL
a	NULL
double-amino-acid	NULL
substitution	NULL
of	NULL
an	NULL
alanine	NULL
and	NULL
serine	NULL
for	NULL
the	NULL
threonine	NULL
and	NULL
leucine	NULL
amino	NULL
acids	NULL
at	NULL
positions	NULL
130	NULL
and	NULL
131	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
M22	NULL
mutant	NULL
is	NULL
defective	NULL
for	NULL
NF-kB	NULL
activation	NULL
,	NULL
but	NULL
the	NULL
mutation	NULL
has	NULL
only	NULL
a	NULL
minimal	NULL
effect	NULL
on	NULL
CREB/ATF	NULL
activity	NULL
(	NULL
69	NULL
)	NULL
.	NULL

Conversely	NULL
,	NULL
the	NULL
M47	NULL
mutation	NULL
is	NULL
a	NULL
substitution	NULL
of	NULL
arginine	NULL
and	NULL
serine	NULL
for	NULL
the	NULL
two	NULL
leucine	NULL
amino	NULL
acid	NULL
residues	NULL
at	NULL
positions	NULL
319	NULL
and	NULL
320	NULL
,	NULL
and	NULL
the	NULL
mutant	NULL
is	NULL
defective	NULL
for	NULL
CREB/ATF	NULL
activation	NULL
while	NULL
retaining	NULL
the	NULL
ability	NULL
to	NULL
activate	NULL
NF-kB	NULL
(	NULL
69	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
M22	NULL
and	NULL
M47	NULL
,	NULL
other	NULL
Tax	NULL
point	NULL
mutations	NULL
have	NULL
been	NULL
described	NULL
which	NULL
also	NULL
selectively	NULL
abrogate	NULL
CREB/ATF	NULL
(	NULL
C298	NULL
,	NULL
H52Q	NULL
,	NULL
L296G	NULL
,	NULL
and	NULL
L320G	NULL
)	NULL
or	NULL
NF-kB	NULL
(	NULL
C23S	NULL
,	NULL
$	NULL
258A	NULL
,	NULL
and	NULL
G148V	NULL
)	NULL
activation	NULL
(	NULL
67	NULL
,	NULL
78	NULL
)	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
these	NULL
mutations	NULL
on	NULL
the	NULL
ability	NULL
of	NULL
Tax	NULL
to	NULL
immortalize	NULL
or	NULL
transform	NULL
various	NULL
cell	NULL
types	NULL
has	NULL
been	NULL
examined	NULL
,	NULL
including	NULL
established	NULL
rat	NULL
fibroblast	NULL
cell	NULL
lines	NULL
and	NULL
primary	NULL
hu-	NULL
voL	NULL
.	NULL

73	NULL
,	NULL
1999	NULL
man	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMC	NULL
)	NULL
(	NULL
2	NULL
,	NULL
62	NULL
,	NULL
70	NULL
,	NULL
78	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
results	NULL
of	NULL
these	NULL
studies	NULL
have	NULL
been	NULL
conflict-ing	NULL
,	NULL
and	NULL
no	NULL
overall	NULL
consensus	NULL
has	NULL
been	NULL
reached	NULL
as	NULL
to	NULL
whether	NULL
Tax	NULL
activation	NULL
of	NULL
the	NULL
CREB/ATF	NULL
or	NULL
NF-	NULL
«	NULL
B	NULL
pathway	NULL
is	NULL
critical	NULL
for	NULL
cellular	NULL
immortalization	NULL
or	NULL
transformation	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
effects	NULL
of	NULL
these	NULL
mutations	NULL
on	NULL
the	NULL
ability	NULL
of	NULL
an	NULL
infectious	NULL
molecular	NULL
clone	NULL
of	NULL
HTLV-1	NULL
to	NULL
immortalize	NULL
primary	NULL
human	NULL
PBMC	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
while	NULL
CREB/ATF	NULL
activation	NULL
is	NULL
dispensable	NULL
for	NULL
cellular	NULL
immortalization	NULL
,	NULL
NF-kB	NULL
activation	NULL
appears	NULL
to	NULL
be	NULL
important	NULL
.	NULL

Furthermore	NULL
,	NULL
activation	NULL
of	NULL
CREB/ATF	NULL
by	NULL
Tax	NULL
may	NULL
be	NULL
important	NULL
in	NULL
the	NULL
preferential	NULL
immortalization	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
by	NULL
HTLV-1	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Construction	NULL
of	NULL
ACH	NULL
Tax	NULL
mutants	NULL
.	NULL

Construction	NULL
of	NULL
the	NULL
ACH	NULL
molecular	NULL
clone	NULL
of	NULL
HTLV-1	NULL
has	NULL
been	NULL
previously	NULL
described	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Tax	NULL
expression	NULL
clones	NULL
containing	NULL
wild-type	NULL
Tax	NULL
(	NULL
peTax	NULL
)	NULL
,	NULL
the	NULL
M22	NULL
mutation	NULL
,	NULL
and	NULL
the	NULL
M47	NULL
mutation	NULL
were	NULL
generous	NULL
gifts	NULL
from	NULL
Warner	NULL
C.	NULL
Greene	NULL
(	NULL
61	NULL
,	NULL
69	NULL
)	NULL
.	NULL

The	NULL
Tax	NULL
expression	NULL
clones	NULL
were	NULL
digested	NULL
with	NULL
Accl	NULL
and	NULL
Smal	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Beverly	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

,	NULL
and	NULL
a	NULL
961-bp	NULL
fragment	NULL
encoding	NULL
amino	NULL
acids	NULL
18	NULL
to	NULL
336	NULL
of	NULL
Tax	NULL
was	NULL
cloned	NULL
into	NULL
an	NULL
Accl-SmeI-digested	NULL
ACH	NULL
subclone	NULL
(	NULL
ACHAKpnI	NULL
)	NULL
,	NULL
which	NULL
consists	NULL
of	NULL
nucleotides	NULL
6121	NULL
to	NULL
11813	NULL
of	NULL
the	NULL
ACH	NULL
plasmid	NULL
.	NULL

A	NULL
2,344-bp	NULL
Nsil-EcoRI	NULL
fragment	NULL
from	NULL
ACHAKpnI	NULL
was	NULL
then	NULL
cloned	NULL
into	NULL
Nsil-EcoRI-digested	NULL
ACH	NULL
to	NULL
generate	NULL
ACH.pcTax	NULL
,	NULL
ACH.M22	NULL
,	NULL
and	NULL
ACH.M47	NULL
.	NULL

Viral	NULL
particle	NULL
production	NULL
assay	NULL
.	NULL

Human	NULL
293T	NULL
kidney	NULL
fibroblasts	NULL
seeded	NULL
to	NULL
30	NULL
%	NULL
confluence	NULL
in	NULL
10-cm-diameter	NULL
dishes	NULL
were	NULL
transfected	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
ACH	NULL
peTax	NULL
,	NULL
ACH.M22	NULL
,	NULL
ACH.M47	NULL
,	NULL
or	NULL
pBluescript	NULL
KS	NULL
(	NULL
Stratagene	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
Calif.	NULL
)	NULL
(	NULL
empty	NULL
vector	NULL
)	NULL
with	NULL
30	NULL
wl	NULL
of	NULL
Lipofectamine	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Gaithersburg	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

in	NULL
OPTI-MEM	NULL
I	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
.	NULL

After	NULL
transfection	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
,	NULL
2	NULL
mM	NULL
r-glutamine	NULL
,	NULL
50	NULL
pg	NULL
of	NULL
penicillin/ml	NULL
,	NULL
and	NULL
50	NULL
U	NULL
of	NULL
streptomycin/ml	NULL
.	NULL

Cell	NULL
culture	NULL
supernatants	NULL
were	NULL
collected	NULL
at	NULL
various	NULL
time	NULL
points	NULL
posttransfection	NULL
,	NULL
and	NULL
virus	NULL
particle	NULL
production	NULL
was	NULL
monitored	NULL
by	NULL
p19	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
(	NULL
ELISA	NULL
)	NULL
(	NULL
Cellular	NULL
Products	NULL
,	NULL
Buffalo	NULL
,	NULL
N.Y.	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

Transfection	NULL
of	NULL
PBMC	NULL
.	NULL

Human	NULL
PBMC	NULL
were	NULL
purified	NULL
from	NULL
healthy	NULL
donors	NULL
by	NULL
Ficoll-Paque	NULL
(	NULL
Pharmacia	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
Calif.	NULL
)	NULL
centrifugation	NULL
and	NULL
activated	NULL
for	NULL
72	NULL
h	NULL
with	NULL
10	NULL
jg	NULL
of	NULL
phytohemagglutinin-P	NULL
(	NULL
PHA	NULL
)	NULL
(	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
Mo	NULL
.	NULL
)	NULL

/ml	NULL
and	NULL
50	NULL
U	NULL
of	NULL
recombinant	NULL
human	NULL
IL-2/ml	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
,	NULL
2	NULL
mM	NULL
1-glutamine	NULL
,	NULL
50	NULL
pg	NULL
of	NULL
penicillin/ml	NULL
,	NULL
and	NULL
50	NULL
U	NULL
of	NULL
streptomycin/ml	NULL
(	NULL
cRPMI	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
electroporated	NULL
with	NULL
25	NULL
ug	NULL
of	NULL
ACH	NULL
plasmid	NULL
at	NULL
250	NULL
V	NULL
,	NULL
1,800	NULL
pF	NULL
capacitance	NULL
,	NULL
and	NULL
720	NULL
{	NULL
resistance	NULL
with	NULL
an	NULL
ECM	NULL
600	NULL
electroporation	NULL
apparatus	NULL
(	NULL
BTX	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
cultured	NULL
in	NULL
cRPMI	NULL
supplemented	NULL
with	NULL
5	NULL
pg	NULL
of	NULL
PHA/ml	NULL
and	NULL
50	NULL
U	NULL
of	NULL
IL-2/ml	NULL
for	NULL
6	NULL
weeks	NULL
,	NULL
after	NULL
which	NULL
they	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
same	NULL
medium	NULL
without	NULL
PHA	NULL
.	NULL

At	NULL
various	NULL
time	NULL
points	NULL
,	NULL
cell	NULL
culture	NULL
supernatants	NULL
were	NULL
collected	NULL
for	NULL
p19	NULL
determination	NULL
,	NULL
and	NULL
relative	NULL
cellular	NULL
viability	NULL
was	NULL
assayed	NULL
by	NULL
MTT	NULL
conversion	NULL
assays	NULL
on	NULL
100-pl	NULL
aliquots	NULL
of	NULL
cells	NULL
as	NULL
described	NULL
by	NULL
Hansen	NULL
et	NULL
al	NULL
.	NULL

(	NULL
19	NULL
)	NULL
.	NULL

PCR	NULL
amplification	NULL
of	NULL
Tax	NULL
.	NULL

Genomic	NULL
DNA	NULL
was	NULL
purified	NULL
from	NULL
ACH.pcTax-	NULL
and	NULL
ACH.M47-immortalized	NULL
cell	NULL
lines	NULL
by	NULL
the	NULL
Wizard	NULL
Prep	NULL
genomic	NULL
DNA	NULL
purification	NULL
system	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
Wis.	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

PCR	NULL
(	NULL
95°C	NULL
for	NULL
1	NULL
min	NULL
;	NULL
60°C	NULL
for	NULL
2	NULL
min	NULL
;	NULL
72°C	NULL
for	NULL
3	NULL
ming	NULL
35	NULL
cycles	NULL
)	NULL
was	NULL
performed	NULL
on	NULL
200	NULL
ng	NULL
of	NULL
genomic	NULL
DNA	NULL
with	NULL
the	NULL
following	NULL
primers	NULL
:	NULL
5'-CGGAA	NULL
TTCATGGCCCACTTCCCAGGGTTTGG-3	NULL
'	NULL
and	NULL
5-CGGGATCCCTAGTC	NULL
ACTTAGACTTCTGTITCTCGGAAATG-3	NULL
'	NULL
,	NULL
which	NULL
amplifies	NULL
the	NULL
entire	NULL
Tax	NULL
open	NULL
reading	NULL
frame	NULL
(	NULL
ORF	NULL
)	NULL
.	NULL

The	NULL
PCR	NULL
product	NULL
was	NULL
then	NULL
digested	NULL
with	NULL
Bg/ll	NULL
to	NULL
assess	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
M47	NULL
mutation	NULL
.	NULL

Alternatively	NULL
,	NULL
the	NULL
PCR	NULL
product	NULL
was	NULL
digested	NULL
with	NULL
Accl	NULL
and	NULL
XmaI	NULL
and	NULL
cloned	NULL
into	NULL
Accl-Xmal-digested	NULL
Tax	NULL
expression	NULL
plasmid	NULL
pIEX	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
O.	NULL
John	NULL
Semmes	NULL
)	NULL
.	NULL

For	NULL
activity	NULL
determination	NULL
,	NULL
5	NULL
ug	NULL
of	NULL
each	NULL
Tax	NULL
expression	NULL
clone	NULL
was	NULL
cotransfected	NULL
with	NULL
1	NULL
pg	NULL
of	NULL
HTLV	NULL
LTR-luciferase	NULL
in	NULL
293T	NULL
cells	NULL
with	NULL
Lipofectamine	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
harvested	NULL
24	NULL
h	NULL
posttransfection	NULL
and	NULL
lysed	NULL
by	NULL
repeated	NULL
freeze-thaw	NULL
(	NULL
four	NULL
times	NULL
)	NULL
in	NULL
0.25	NULL
M	NULL
Tris	NULL
(	NULL
pH	NULL
7.8	NULL
)	NULL
,	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
measured	NULL
with	NULL
an	NULL
OPTOCOMP	NULL
I	NULL
luminom-eter	NULL
(	NULL
MGM	NULL
Instruments	NULL
,	NULL
Hamden	NULL
,	NULL
Conn.	NULL
)	NULL
.	NULL

Western	NULL
immunoblotting	NULL
for	NULL
Tax	NULL
in	NULL
immortalized	NULL
cell	NULL
extracts	NULL
.	NULL

Ten	NULL
million	NULL
cells	NULL
were	NULL
lysed	NULL
by	NULL
incubation	NULL
at	NULL
4°C	NULL
for	NULL
30	NULL
min	NULL
in	NULL
500	NULL
pl	NULL
of	NULL
RIPA	NULL
buffer	NULL
(	NULL
50	NULL
mM	NULL
Tris	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
0.1	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
,	NULL
1.0	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
0.5	NULL
%	NULL
sodium	NULL
deoxycholate	NULL
,	NULL
0.5	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
,	NULL
1	NULL
wg	NULL
of	NULL
leupeptin/	NULL
ml	NULL
,	NULL
5	NULL
pg	NULL
of	NULL
pepstatin	NULL
A/ml	NULL
,	NULL
and	NULL
8	NULL
pg	NULL
of	NULL
aprotinin	NULL
[	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
Mo	NULL
.	NULL
]	NULL

/ml	NULL
)	NULL
.	NULL

Cellular	NULL
debris	NULL
was	NULL
removed	NULL
by	NULL
centrifugation	NULL
at	NULL
8,000	NULL
x	NULL
g	NULL
for	NULL
20	NULL
min	NULL
,	NULL
and	NULL
100	NULL
ul	NULL
of	NULL
cleared	NULL
extract	NULL
was	NULL
electrophoresed	NULL
by	NULL
sodium	NULL
dodecyl	NULL
sulfate-polyacryl-amide	NULL
gel	NULL
electrophoresis	NULL
.	NULL

After	NULL
transfer	NULL
to	NULL
a	NULL
nitrocellulose	NULL
membrane	NULL
,	NULL
the	NULL
blot	NULL
was	NULL
sequentially	NULL
probed	NULL
with	NULL
pooled	NULL
anti-Tax	NULL
monoclonal	NULL
antibodies	NULL
(	NULL
no	NULL
.	NULL

168A51-2	NULL
,	NULL
168A51-42	NULL
,	NULL
and	NULL
168B17-46-34	NULL
;	NULL
AIDS	NULL
Reagent	NULL
Program	NULL
,	NULL
Rockville	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

(	NULL
38	NULL
)	NULL
and	NULL
anti-mouse	NULL
immunoglobulin	NULL
G-horseradish	NULL
peroxidase-conju-gated	NULL
antibody	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
Calif.	NULL
)	NULL
,	NULL
and	NULL
Tax	NULL
protein	NULL
was	NULL
detected	NULL
by	NULL
chemiluminescence	NULL
.	NULL

IMMORTALIZATION	NULL
OF	NULL
T	NULL
CELLS	NULL
WITH	NULL
HTLV-1	NULL
Tax	NULL
MUTANTS	NULL
-	NULL
4857	NULL
Ae	NULL
ig	NULL
ACH.wt	NULL
|	NULL
|	NULL
ACH.pcTax	NULL
ACH.M22	NULL
ACH.M47	NULL
I	NULL
:	NULL
=	NULL
strain	NULL
CH	NULL
Tax	NULL
=	NULL
strain	NULL
C91/PL	NULL
Tax	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Construction	NULL
of	NULL
ACH	NULL
Tax	NULL
mutants	NULL
.	NULL

The	NULL
ACH.pcTax	NULL
,	NULL
ACH.M22	NULL
,	NULL
and	NULL
ACH.M47	NULL
constructs	NULL
used	NULL
in	NULL
this	NULL
study	NULL
contain	NULL
the	NULL
fax	NULL
gene	NULL
of	NULL
the	NULL
HTLV-1	NULL
strain	NULL
C91/PL	NULL
between	NULL
the	NULL
Accl	NULL
site	NULL
at	NULL
position	NULL
7346	NULL
and	NULL
the	NULL
Smel	NULL
site	NULL
at	NULL
position	NULL
8307	NULL
in	NULL
the	NULL
ACH	NULL
molecular	NULL
clone	NULL
.	NULL

The	NULL
M22	NULL
mutation	NULL
results	NULL
in	NULL
a	NULL
Thr	NULL
'	NULL
``	NULL
%	NULL
Leu'*'-to-Ala	NULL
``	NULL
``	NULL
``	NULL
Ser	NULL
'	NULL
>	NULL
*	NULL
substitution	NULL
,	NULL
while	NULL
the	NULL
M47	NULL
mutation	NULL
is	NULL
a	NULL
Leu*Leu	NULL
``	NULL
``	NULL
``	NULL
-to-Arg	NULL
``	NULL
Ser	NULL
``	NULL
substitution	NULL
.	NULL

Transfection	NULL
of	NULL
immortalized	NULL
cell	NULL
lines	NULL
.	NULL

Twenty	NULL
million	NULL
ACH.pcTax-	NULL
or	NULL
ACH.M47-immortalized	NULL
cells	NULL
or	NULL
PHA-IL-2-stimulated	NULL
PBMC	NULL
were	NULL
transfected	NULL
by	NULL
electroporation	NULL
(	NULL
250V	NULL
;	NULL
1,800	NULL
wF	NULL
;	NULL
720	NULL
0	NULL
)	NULL
with	NULL
20	NULL
ug	NULL
of	NULL
HTLV	NULL
LTR-luciferase	NULL
and	NULL
5	NULL
pg	NULL
of	NULL
a	NULL
cytomegalovirus	NULL
(	NULL
CMV	NULL
)	NULL
enhancer-chloramphenicol	NULL
acetyltrans-ferase	NULL
(	NULL
CAT	NULL
)	NULL
expression	NULL
plasmid	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
harvested	NULL
24	NULL
h	NULL
posttransfection	NULL
,	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
30	NULL
g	NULL
of	NULL
whole-cell	NULL
extract	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Transfection	NULL
efficiency	NULL
was	NULL
normalized	NULL
by	NULL
measurement	NULL
of	NULL
CAT	NULL
activity	NULL
in	NULL
3	NULL
pg	NULL
of	NULL
cell	NULL
extracts	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
determined	NULL
by	NULL
phase	NULL
extraction	NULL
of	NULL
butyrated	NULL
chloramphenicol	NULL
with	NULL
xylenes	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Infection	NULL
of	NULL
PBMC	NULL
and	NULL
microtiter	NULL
infectivity	NULL
assay	NULL
.	NULL

For	NULL
the	NULL
viral	NULL
replication	NULL
assay	NULL
,	NULL
5	NULL
X	NULL
10°	NULL
PCTAX-2	NULL
and	NULL
M47-3	NULL
cells	NULL
were	NULL
lethally	NULL
gamma	NULL
irradiated	NULL
(	NULL
6,000	NULL
rads	NULL
)	NULL
and	NULL
cocultured	NULL
with	NULL
5	NULL
X	NULL
10°	NULL
PBMC	NULL
activated	NULL
with	NULL
PHA	NULL
and	NULL
IL-2	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
cRPMI	NULL
supplemented	NULL
with	NULL
50	NULL
U	NULL
of	NULL
IL-2/ml	NULL
,	NULL
and	NULL
supernatants	NULL
were	NULL
collected	NULL
at	NULL
various	NULL
time	NULL
points	NULL
and	NULL
assayed	NULL
for	NULL
virus	NULL
particles	NULL
by	NULL
p19	NULL
ELISA	NULL
.	NULL

The	NULL
microtiter	NULL
infectivity	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
by	NULL
Persaud	NULL
et	NULL
al	NULL
.	NULL

(	NULL
54	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
10°	NULL
PHAIL-2-activated	NULL
PBMC	NULL
were	NULL
cocultured	NULL
with	NULL
either	NULL
10°	NULL
,	NULL
10°	NULL
,	NULL
or	NULL
10	NULL
lethally	NULL
irradiated	NULL
(	NULL
6,000	NULL
rads	NULL
)	NULL
PCTAX-2	NULL
,	NULL
PCTAX-3	NULL
,	NULL
M47-2	NULL
,	NULL
or	NULL
M47-3	NULL
cells	NULL
in	NULL
replicates	NULL
of	NULL
20	NULL
at	NULL
each	NULL
dilution	NULL
in	NULL
96-well	NULL
microtiter	NULL
plates	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
cRPMI	NULL
with	NULL
50	NULL
U	NULL
of	NULL
IL-2/ml	NULL
were	NULL
split	NULL
1:2	NULL
approximately	NULL
once	NULL
per	NULL
week	NULL
.	NULL

At	NULL
8	NULL
to	NULL
10	NULL
weeks	NULL
postcoculture	NULL
,	NULL
individual	NULL
wells	NULL
were	NULL
examined	NULL
microscopically	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
viable	NULL
cells	NULL
.	NULL

FACS	NULL
analysis	NULL
of	NULL
immortalized	NULL
cell	NULL
lines	NULL
.	NULL

One	NULL
million	NULL
ACH.pcTax-	NULL
or	NULL
ACH.M47-immortalized	NULL
cells	NULL
were	NULL
washed	NULL
in	NULL
fluorescence-activated	NULL
cell	NULL
sorter	NULL
(	NULL
FACS	NULL
)	NULL
staining	NULL
buffer	NULL
(	NULL
1	NULL
%	NULL
phosphate-buffered	NULL
saline	NULL
,	NULL
10	NULL
%	NULL
FCS	NULL
,	NULL
0.05	NULL
%	NULL
sodium	NULL
azide	NULL
)	NULL
and	NULL
incubated	NULL
in	NULL
the	NULL
same	NULL
buffer	NULL
for	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
with	NULL
mouse	NULL
anti-human	NULL
CD3-phycoerytherin	NULL
(	NULL
PE	NULL
)	NULL
,	NULL
anti-CD25-PE	NULL
,	NULL
anti-CD4-fluorescein	NULL
isothiocyanate	NULL
,	NULL
or	NULL
anti	NULL
CD8-PE	NULL
(	NULL
Pharmingen	NULL
)	NULL
.	NULL

The	NULL
stained	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
in	NULL
the	NULL
staining	NULL
buffer	NULL
,	NULL
fixed	NULL
in	NULL
1	NULL
%	NULL
paraformaldehyde-phosphate-buffered	NULL
saline	NULL
,	NULL
and	NULL
analyzed	NULL
on	NULL
a	NULL
FACSCalibur	NULL
flow	NULL
cytometer	NULL
(	NULL
Becton-Dickinson	NULL
,	NULL
San	NULL
Jose	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

RESULTS	NULL
Construction	NULL
and	NULL
activity	NULL
of	NULL
ACH	NULL
Tax	NULL
mutants	NULL
.	NULL

A	NULL
molecular	NULL
clone	NULL
of	NULL
HTLV-1	NULL
known	NULL
as	NULL
ACH	NULL
,	NULL
which	NULL
produces	NULL
infectious	NULL
viral	NULL
particles	NULL
capable	NULL
of	NULL
immortalizing	NULL
primary	NULL
human	NULL
lymphocytes	NULL
and	NULL
establishing	NULL
productive	NULL
infections	NULL
in	NULL
rabbits	NULL
,	NULL
has	NULL
been	NULL
previously	NULL
described	NULL
(	NULL
11	NULL
,	NULL
34	NULL
)	NULL
.	NULL

The	NULL
ACH	NULL
Tax	NULL
mutant	NULL
clones	NULL
were	NULL
constructed	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
and	NULL
are	NULL
diagrammed	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

The	NULL
resulting	NULL
ACH	NULL
Tax	NULL
mutant	NULL
clones	NULL
contained	NULL
the	NULL
tax	NULL
gene	NULL
from	NULL
HTLV-1	NULL
C91/PL	NULL
between	NULL
nucleotides	NULL
7346	NULL
and	NULL
8307	NULL
,	NULL
which	NULL
differs	NULL
from	NULL
the	NULL
CH	NULL
strain	NULL
in	NULL
the	NULL
ACH	NULL
clone	NULL
by	NULL
5	NULL
amino	NULL
acid	NULL
codons	NULL
.	NULL

As	NULL
the	NULL
first	NULL
17	NULL
4858	NULL
ROBEK	NULL
AND	NULL
RATNER	NULL
TABLE	NULL
1	NULL
.	NULL

Activity	NULL
of	NULL
Tax	NULL
mutants	NULL
and	NULL
summary	NULL
of	NULL
immortalization	NULL
assays	NULL
Activity	NULL
(	NULL
%	NULL
)	NULL
``	NULL
immortalized	NULL
Clone	NULL
cultures/Hf	NULL
)	NULL
.	NULL

of	NULL
HTLV	NULL
HIV	NULL
(	NULL
transffczitlons	NULL
f	NULL
no	NULL
.	NULL

of	NULL
donor	NULL
LTR-luciferase	NULL
LTR-CAT	NULL
PBMC	NULL
)	NULL
ACH.wt	NULL
ND	NULL
ND	NULL
4/5	NULL
(	NULL
5	NULL
)	NULL
ACH.pcTax	NULL
100	NULL
100	NULL
5/6	NULL
(	NULL
4	NULL
)	NULL
ACH.M22	NULL
80	NULL
7	NULL
0/6	NULL
(	NULL
4	NULL
)	NULL
ACH.M47	NULL
2	NULL
138	NULL
5/5	NULL
(	NULL
4	NULL
)	NULL
Empty	NULL
vector	NULL
0	NULL
0	NULL
0/8	NULL
(	NULL
7	NULL
)	NULL
``	NULL
Luciferase	NULL
or	NULL
CAT	NULL
activity	NULL
above	NULL
empty	NULL
vector	NULL
cotransfection	NULL
normalized	NULL
to	NULL
100	NULL
%	NULL
for	NULL
the	NULL
wild-type	NULL
ACH.pcTax	NULL
clone	NULL
.	NULL

A	NULL
100	NULL
%	NULL
activity	NULL
corresponds	NULL
to	NULL
an	NULL
approximately	NULL
20-fold	NULL
increase	NULL
in	NULL
luciferase	NULL
activity	NULL
for	NULL
HTLV	NULL
LTR-luciferase	NULL
and	NULL
a	NULL
2-fold	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
for	NULL
HIV	NULL
LTR-CAT	NULL
.	NULL

ND	NULL
,	NULL
not	NULL
done	NULL
.	NULL

and	NULL
the	NULL
last	NULL
7	NULL
amino	NULL
acids	NULL
are	NULL
identical	NULL
in	NULL
the	NULL
CH	NULL
and	NULL
C91/PL	NULL
strains	NULL
,	NULL
the	NULL
resulting	NULL
fax	NULL
gene	NULL
in	NULL
the	NULL
ACH	NULL
clones	NULL
is	NULL
identical	NULL
to	NULL
C91/PL	NULL
tax	NULL
.	NULL

Since	NULL
the	NULL
C91/PL	NULL
and	NULL
CH	NULL
strains	NULL
differ	NULL
by	NULL
5	NULL
amino	NULL
acids	NULL
,	NULL
we	NULL
also	NULL
constructed	NULL
a	NULL
positive	NULL
control	NULL
clone	NULL
which	NULL
contained	NULL
wild-type	NULL
C91/PL	NULL
tax	NULL
(	NULL
ACH.pcTax	NULL
)	NULL
.	NULL

The	NULL
CREB/ATEF-and	NULL
NF-	NULL
«	NULL
B-activating	NULL
activities	NULL
of	NULL
the	NULL
M22	NULL
and	NULL
M47	NULL
mutants	NULL
have	NULL
been	NULL
previously	NULL
examined	NULL
in	NULL
a	NULL
number	NULL
of	NULL
cell	NULL
lines	NULL
and	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
expression	NULL
systems	NULL
(	NULL
2	NULL
,	NULL
69	NULL
)	NULL
.	NULL

However	NULL
,	NULL
we	NULL
wanted	NULL
to	NULL
confirm	NULL
that	NULL
these	NULL
mutants	NULL
had	NULL
the	NULL
expected	NULL
activities	NULL
with	NULL
respect	NULL
to	NULL
CREB	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
when	NULL
expressed	NULL
from	NULL
the	NULL
ACH	NULL
clone	NULL
.	NULL

The	NULL
ACH.pcTax	NULL
,	NULL
ACH.M22	NULL
,	NULL
and	NULL
ACH.M47	NULL
clones	NULL
were	NULL
cotransfected	NULL
with	NULL
either	NULL
an	NULL
HTLV	NULL
LTR-luciferase	NULL
reporter	NULL
construct	NULL
or	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
LTR-CAT	NULL
reporter	NULL
construct	NULL
in	NULL
human	NULL
293T	NULL
kidney	NULL
fibroblasts	NULL
,	NULL
and	NULL
luciferase	NULL
or	NULL
CAT	NULL
activity	NULL
was	NULL
measured	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
the	NULL
ACH.M47	NULL
clone	NULL
expressed	NULL
a	NULL
Tax	NULL
protein	NULL
which	NULL
failed	NULL
to	NULL
transactivate	NULL
the	NULL
HTLV	NULL
LTR-luciferase	NULL
construct	NULL
,	NULL
which	NULL
is	NULL
dependent	NULL
on	NULL
CREB	NULL
,	NULL
but	NULL
had	NULL
wild-type	NULL
activity	NULL
for	NULL
the	NULL
HIV	NULL
LTR-CAT	NULL
reporter	NULL
plasmid	NULL
,	NULL
which	NULL
is	NULL
activated	NULL
by	NULL
NF-kB	NULL
.	NULL

Conversely	NULL
,	NULL
the	NULL
ACHM22	NULL
clone	NULL
expressed	NULL
a	NULL
Tax	NULL
protein	NULL
which	NULL
activated	NULL
the	NULL
HTLV	NULL
LTR	NULL
to	NULL
near-wild-type	NULL
levels	NULL
but	NULL
did	NULL
not	NULL
activate	NULL
the	NULL
HIV	NULL
LTR	NULL
.	NULL

Therefore	NULL
,	NULL
when	NULL
expressed	NULL
from	NULL
the	NULL
ACH	NULL
clone	NULL
,	NULL
the	NULL
M22	NULL
and	NULL
M47	NULL
Tax	NULL
mutants	NULL
have	NULL
the	NULL
originally	NULL
described	NULL
activity	NULL
with	NULL
respect	NULL
to	NULL
CREB	NULL
and	NULL
NF-kB	NULL
activation	NULL
.	NULL

Viral	NULL
particle	NULL
production	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
abilities	NULL
of	NULL
the	NULL
ACH.pcTax	NULL
,	NULL
ACH.M22	NULL
,	NULL
and	NULL
ACH.M47	NULL
clones	NULL
to	NULL
produce	NULL
viral	NULL
particles	NULL
,	NULL
293T	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
each	NULL
clone	NULL
and	NULL
viral	NULL
particle	NULL
production	NULL
was	NULL
assayed	NULL
by	NULL
p19	NULL
antigen	NULL
ELISA	NULL
approximately	NULL
every	NULL
24	NULL
h	NULL
posttransfection	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

The	NULL
ACH.pcTax	NULL
and	NULL
ACH.M22	NULL
clones	NULL
were	NULL
both	NULL
capable	NULL
of	NULL
producing	NULL
relatively	NULL
high	NULL
levels	NULL
of	NULL
viral	NULL
particles	NULL
,	NULL
with	NULL
up	NULL
to	NULL
15,000	NULL
pg	NULL
of	NULL
p19	NULL
antigen/ml	NULL
being	NULL
detected	NULL
in	NULL
the	NULL
culture	NULL
supernatants	NULL
at	NULL
90	NULL
h	NULL
posttransfection	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
M22	NULL
mutation	NULL
in	NULL
the	NULL
ACH	NULL
clone	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
affect	NULL
viral	NULL
particle	NULL
production	NULL
,	NULL
as	NULL
would	NULL
be	NULL
expected	NULL
from	NULL
its	NULL
ability	NULL
to	NULL
activate	NULL
the	NULL
HTLV	NULL
LTR-luciferase	NULL
construct	NULL
efficiently	NULL
.	NULL

This	NULL
result	NULL
rules	NULL
out	NULL
any	NULL
major	NULL
defect	NULL
in	NULL
the	NULL
Rex	NULL
protein	NULL
,	NULL
a	NULL
splicing	NULL
regulator	NULL
required	NULL
for	NULL
efficient	NULL
gag	NULL
expression	NULL
(	NULL
26	NULL
,	NULL
27	NULL
)	NULL
,	NULL
whose	NULL
ORF	NULL
overlaps	NULL
that	NULL
of	NULL
Tax	NULL
and	NULL
in	NULL
which	NULL
the	NULL
M22	NULL
mutation	NULL
also	NULL
changes	NULL
two	NULL
amino	NULL
acids	NULL
(	NULL
Pro'*Cys*	NULL
``	NULL
°	NULL
to	NULL
Leu	NULL
``	NULL
Ala	NULL
``	NULL
``	NULL
``	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
ACH.M47	NULL
clone	NULL
produced	NULL
much	NULL
lower	NULL
amounts	NULL
of	NULL
virus	NULL
in	NULL
this	NULL
transient	NULL
transfection	NULL
assay	NULL
,	NULL
with	NULL
approximately	NULL
400	NULL
pg	NULL
of	NULL
p19/ml	NULL
being	NULL
detected	NULL
by	NULL
90	NULL
h	NULL
posttransfection	NULL
.	NULL

This	NULL
result	NULL
was	NULL
expected	NULL
due	NULL
to	NULL
the	NULL
defect	NULL
in	NULL
LTR	NULL
activation	NULL
by	NULL
the	NULL
M47	NULL
mutant	NULL
.	NULL

Immortalization	NULL
of	NULL
primary	NULL
human	NULL
lymphocytes	NULL
.	NULL

To	NULL
test	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
ACH	NULL
Tax	NULL
mutant	NULL
clones	NULL
to	NULL
induce	NULL
immortaliza-	NULL
J.	NULL
Virou	NULL
.	NULL

-DO-ACH.peTax	NULL
-i-	NULL
ACH	NULL
.	NULL

M22	NULL
100,000	NULL
7	NULL
-J-	NULL
ACH.M47	NULL
-S-	NULL
Vector	NULL
Alone	NULL
E	NULL
10,000	NULL
+	NULL
o	NULL
Res	NULL
g	NULL
)	NULL
1,000	NULL
+	NULL
b=	NULL
<	NULL
CN	NULL
'	NULL
a	NULL
.	NULL

-	NULL
100	NULL
4	NULL
10	NULL
+	NULL
--	NULL
-0	NULL
20	NULL
40	NULL
60	NULL
80	NULL
100	NULL
Hours	NULL
Post-Transfection	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Viral	NULL
particle	NULL
production	NULL
by	NULL
ACH	NULL
Tax	NULL
mutants	NULL
.	NULL

Human	NULL
293T	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
ACH.pcTax	NULL
,	NULL
ACH.M22	NULL
,	NULL
and	NULL
ACH.M47	NULL
clones	NULL
or	NULL
empty	NULL
vector	NULL
,	NULL
and	NULL
viral	NULL
particle	NULL
production	NULL
was	NULL
measured	NULL
by	NULL
p19	NULL
antigen	NULL
ELISA	NULL
.	NULL

The	NULL
error	NULL
bars	NULL
indicate	NULL
the	NULL
standard	NULL
deviations	NULL
of	NULL
three	NULL
replicate	NULL
transfections	NULL
.	NULL

Whereas	NULL
the	NULL
ACH.M22	NULL
clone	NULL
produces	NULL
viral	NULL
particles	NULL
at	NULL
amounts	NULL
similar	NULL
to	NULL
wild-type	NULL
levels	NULL
,	NULL
the	NULL
ACH.M47	NULL
clone	NULL
produces	NULL
much	NULL
lower	NULL
levels	NULL
of	NULL
virus	NULL
.	NULL

tion	NULL
,	NULL
20	NULL
million	NULL
Ficoll-Paque-purified	NULL
human	NULL
PBMC	NULL
were	NULL
activated	NULL
with	NULL
10	NULL
pg	NULL
of	NULL
PHA/ml	NULL
and	NULL
50	NULL
U	NULL
of	NULL
IL-2/ml	NULL
for	NULL
72	NULL
h	NULL
and	NULL
transfected	NULL
by	NULL
electroporation	NULL
with	NULL
the	NULL
ACH.wt	NULL
,	NULL
ACH.pcTax	NULL
,	NULL
ACH.M47	NULL
,	NULL
and	NULL
ACH.M22	NULL
plasmids	NULL
.	NULL

Cellular	NULL
viability	NULL
was	NULL
monitored	NULL
by	NULL
MTT	NULL
conversion	NULL
assays	NULL
.	NULL

An	NULL
example	NULL
of	NULL
one	NULL
experiment	NULL
,	NULL
in	NULL
which	NULL
two	NULL
separate	NULL
transfections	NULL
were	NULL
done	NULL
with	NULL
ACH.pcTax	NULL
and	NULL
ACH.M47	NULL
and	NULL
three	NULL
transfections	NULL
were	NULL
done	NULL
with	NULL
ACH.M22	NULL
,	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
the	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
ACH.wt	NULL
and	NULL
ACH.peTax	NULL
clones	NULL
continued	NULL
to	NULL
proliferate	NULL
indefinitely	NULL
while	NULL
the	NULL
mock-transfected	NULL
cells	NULL
proliferated	NULL
transiently	NULL
and	NULL
died	NULL
by	NULL
approximately	NULL
60	NULL
days	NULL
posttransfection	NULL
.	NULL

Interestingly	NULL
,	NULL
like	NULL
the	NULL
mock-transfected	NULL
cells	NULL
,	NULL
the	NULL
ACH.M22-transfected	NULL
cells	NULL
also	NULL
ceased	NULL
to	NULL
proliferate	NULL
.	NULL

Sur-prisingly	NULL
,	NULL
the	NULL
ACH.M47-transfected	NULL
cells	NULL
also	NULL
became	NULL
immortalized	NULL
,	NULL
despite	NULL
the	NULL
fact	NULL
that	NULL
virus	NULL
produced	NULL
by	NULL
this	NULL
clone	NULL
is	NULL
not	NULL
predicted	NULL
to	NULL
replicate	NULL
as	NULL
efficiently	NULL
as	NULL
ACH.wt-	NULL
or	NULL
ACH.pcTax-derived	NULL
virus	NULL
.	NULL

PBMC	NULL
from	NULL
multiple	NULL
donors	NULL
were	NULL
likewise	NULL
transfected	NULL
and	NULL
monitored	NULL
,	NULL
and	NULL
the	NULL
results	NULL
are	NULL
summarized	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
while	NULL
CREB/ATF	NULL
activation	NULL
activity	NULL
appears	NULL
to	NULL
be	NULL
dispensable	NULL
for	NULL
immortalization	NULL
of	NULL
primary	NULL
PBMC	NULL
,	NULL
NF-kB	NULL
activation	NULL
by	NULL
Tax	NULL
may	NULL
be	NULL
important	NULL
for	NULL
cellular	NULL
immortalization	NULL
.	NULL

Three	NULL
ACH.pcTax-immortalized	NULL
cell	NULL
lines	NULL
and	NULL
three	NULL
ACH.M47-immortalized	NULL
cell	NULL
lines	NULL
were	NULL
chosen	NULL
for	NULL
further	NULL
analysis	NULL
and	NULL
will	NULL
be	NULL
referred	NULL
to	NULL
as	NULL
PCTAX-1	NULL
,	NULL
PCTAX-2	NULL
,	NULL
PCTAX-3	NULL
,	NULL
M47-1	NULL
,	NULL
M47-2	NULL
,	NULL
and	NULL
M47-3	NULL
.	NULL

The	NULL
PCTAX-1	NULL
and	NULL
MA47-1	NULL
cell	NULL
lines	NULL
were	NULL
derived	NULL
from	NULL
PBMC	NULL
from	NULL
the	NULL
same	NULL
donor	NULL
,	NULL
whereas	NULL
the	NULL
PCTAX-2	NULL
,	NULL
PCTAX-3	NULL
,	NULL
M47-2	NULL
,	NULL
and	NULL
M47-3	NULL
cell	NULL
lines	NULL
were	NULL
derived	NULL
from	NULL
PBMC	NULL
of	NULL
a	NULL
different	NULL
donor	NULL
.	NULL

These	NULL
cell	NULL
lines	NULL
were	NULL
examined	NULL
for	NULL
cell	NULL
surface	NULL
marker	NULL
expression	NULL
by	NULL
FACS	NULL
analysis	NULL
,	NULL
and	NULL
all	NULL
were	NULL
determined	NULL
to	NULL
be	NULL
activated	NULL
T	NULL
cells	NULL
based	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
CD3	NULL
and	NULL
CD25	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
CD4	NULL
and	NULL
CD8	NULL
,	NULL
however	NULL
,	NULL
was	NULL
varied	NULL
among	NULL
the	NULL
six	NULL
cell	NULL
lines	NULL
.	NULL

Two	NULL
of	NULL
the	NULL
ACH.pcTax-immortalized	NULL
cell	NULL
lines	NULL
were	NULL
CD4*	NULL
CD8	NULL
~	NULL
,	NULL
while	NULL
the	NULL
third	NULL
was	NULL
CD4~	NULL
CD8	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
two	NULL
of	NULL
the	NULL
ACH.M47	NULL
cell	NULL
lines	NULL
were	NULL
CD4~	NULL
CD8*	NULL
,	NULL
while	NULL
one	NULL
expressed	NULL
both	NULL
CD4	NULL
and	NULL
CD8	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
pattern	NULL
of	NULL
proviral	NULL
integra-	NULL
voL	NULL
.	NULL

73	NULL
,	NULL
1999	NULL
-	NULL
@	NULL
-ACH.wt	NULL
-R-	NULL
ACH.pcTax	NULL
(	NULL
x2	NULL
)	NULL
-A-	NULL
ACHLMA47	NULL
-	NULL
(	NULL
x2	NULL
)	NULL
-O-ACH.M22	NULL
(	NULL
x3	NULL
)	NULL
1.60	NULL
7	NULL
1.40	NULL
4+	NULL
1.20	NULL
+	NULL
1.00	NULL
4+	NULL
0.80	NULL
7	NULL
0.60	NULL
<	NULL
0.40	NULL
<	NULL
0.20	NULL
4	NULL
MTT	NULL
Conversion	NULL
(	NULL
O.D	NULL
.	NULL

590	NULL
)	NULL
0.00	NULL
t	NULL
0	NULL
10	NULL
_	NULL
20	NULL
_	NULL
30	NULL
_	NULL
40	NULL
50	NULL
60	NULL
70	NULL
Days	NULL
Post	NULL
Transfection	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Immortalization	NULL
of	NULL
PBMC	NULL
by	NULL
ACH	NULL
Tax	NULL
mutants	NULL
.	NULL

PHA-IL-2-activated	NULL
human	NULL
PBMC	NULL
were	NULL
transfected	NULL
by	NULL
electroporation	NULL
with	NULL
ACH.wt	NULL
(	NULL
one	NULL
replicate	NULL
)	NULL
,	NULL
ACH.pcTax	NULL
(	NULL
two	NULL
replicates	NULL
)	NULL
,	NULL
ACH.M47	NULL
(	NULL
two	NULL
replicates	NULL
)	NULL
,	NULL
and	NULL
ACH.M22	NULL
(	NULL
three	NULL
replicates	NULL
)	NULL
,	NULL
and	NULL
cellular	NULL
viability	NULL
was	NULL
monitored	NULL
by	NULL
MTT	NULL
conversion	NULL
assays	NULL
.	NULL

Like	NULL
the	NULL
clones	NULL
containing	NULL
wild-type	NULL
Tax	NULL
,	NULL
the	NULL
ACH.M47	NULL
clone	NULL
retains	NULL
immortalizing	NULL
activity	NULL
.	NULL

However	NULL
,	NULL
the	NULL
M22	NULL
mutant	NULL
fails	NULL
to	NULL
immortalize	NULL
the	NULL
infected	NULL
cells	NULL
.	NULL

tion	NULL
in	NULL
the	NULL
immortalized	NULL
cells	NULL
,	NULL
Southern	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
on	NULL
BamHI-digested	NULL
genomic	NULL
DNA	NULL
with	NULL
a	NULL
probe	NULL
derived	NULL
from	NULL
an	NULL
8.5-kb	NULL
Sacl	NULL
fragment	NULL
of	NULL
the	NULL
HTLV-1	NULL
genome	NULL
.	NULL

This	NULL
analysis	NULL
revealed	NULL
both	NULL
clonal	NULL
and	NULL
oligoclonal	NULL
patterns	NULL
of	NULL
proviral	NULL
integration	NULL
in	NULL
the	NULL
immortalized	NULL
cells	NULL
and	NULL
a	NULL
lack	NULL
of	NULL
pBluescript	NULL
vector	NULL
sequences	NULL
from	NULL
the	NULL
ACH	NULL
clone	NULL
flanking	NULL
the	NULL
3	NULL
'	NULL
LTR	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
integration	NULL
of	NULL
the	NULL
HTLV-1	NULL
provirus	NULL
occurred	NULL
through	NULL
the	NULL
viral	NULL
replication	NULL
cycle	NULL
and	NULL
not	NULL
through	NULL
random	NULL
integration	NULL
of	NULL
the	NULL
transfected	NULL
plasmid	NULL
.	NULL

Conservation	NULL
of	NULL
M47	NULL
mutation	NULL
and	NULL
lack	NULL
of	NULL
Tax	NULL
activity	NULL
in	NULL
M47-immortalized	NULL
cell	NULL
lines	NULL
.	NULL

One	NULL
potential	NULL
explanation	NULL
for	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
ACH.M47	NULL
mutant	NULL
to	NULL
immortalize	NULL
primary	NULL
PBMC	NULL
despite	NULL
being	NULL
impaired	NULL
for	NULL
replication	NULL
is	NULL
that	NULL
a	NULL
reversion	NULL
may	NULL
have	NULL
occurred	NULL
in	NULL
the	NULL
tax	NULL
gene	NULL
which	NULL
restored	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
M47	NULL
mutant	NULL
Tax	NULL
protein	NULL
to	NULL
activate	NULL
the	NULL
CREB/ATF	NULL
pathway	NULL
.	NULL

To	NULL
assess	NULL
this	NULL
possibility	NULL
,	NULL
the	NULL
tax	NULL
ORF	NULL
was	NULL
PCR	NULL
amplified	NULL
from	NULL
proviral	NULL
genomic	NULL
DNA	NULL
isolated	NULL
from	NULL
the	NULL
three	NULL
ACH.pcTax-and	NULL
three	NULL
ACH	NULL
.	NULL

M47-immortalized	NULL
cultures	NULL
.	NULL

The	NULL
PCR	NULL
product	NULL
was	NULL
then	NULL
digested	NULL
with	NULL
Bg/lII	NULL
,	NULL
which	NULL
is	NULL
diagnostic	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
M47	NULL
mutation	NULL
.	NULL

Whereas	NULL
the	NULL
three	NULL
PCR	NULL
products	NULL
from	NULL
the	NULL
ACH.pcTax-immortalized	NULL
cells	NULL
were	NULL
not	NULL
cleaved	NULL
with	NULL
Bgill	NULL
,	NULL
all	NULL
three	NULL
of	NULL
the	NULL
PCR	NULL
products	NULL
derived	NULL
from	NULL
the	NULL
ACH.M47-immortalized	NULL
cells	NULL
were	NULL
cut	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

This	NULL
analysis	NULL
rules	NULL
out	NULL
the	NULL
possibility	NULL
of	NULL
a	NULL
change	NULL
at	NULL
any	NULL
of	NULL
the	NULL
6	NULL
nucleotides	NULL
which	NULL
comprise	NULL
the	NULL
M47	NULL
mutation	NULL
,	NULL
as	NULL
any	NULL
change	NULL
would	NULL
have	NULL
resulted	NULL
in	NULL
the	NULL
loss	NULL
of	NULL
the	NULL
Bg/II	NULL
site	NULL
.	NULL

Additionally	NULL
,	NULL
the	NULL
PCR	NULL
products	NULL
were	NULL
cloned	NULL
and	NULL
sequenced	NULL
and	NULL
confirmed	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
M47	NULL
mutation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
analysis	NULL
,	NULL
however	NULL
,	NULL
does	NULL
not	NULL
rule	NULL
out	NULL
the	NULL
possibility	NULL
of	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
mutation	NULL
elsewhere	NULL
in	NULL
the	NULL
Tax	NULL
protein	NULL
which	NULL
is	NULL
somehow	NULL
suppressing	NULL
or	NULL
compensating	NULL
for	NULL
the	NULL
2-amino-acid	NULL
M47	NULL
mutation	NULL
.	NULL

To	NULL
examine	NULL
this	NULL
possibility	NULL
,	NULL
the	NULL
Accl-XmelI	NULL
fragment	NULL
containing	NULL
the	NULL
coding	NULL
region	NULL
for	NULL
Tax	NULL
amino	NULL
acids	NULL
18	NULL
to	NULL
336	NULL
from	NULL
the	NULL
above-described	NULL
PCR	NULL
products	NULL
were	NULL
cloned	NULL
into	NULL
a	NULL
CMV	NULL
promoter-driven	NULL
Tax	NULL
expression	NULL
clone	NULL
(	NULL
pIEX	NULL
;	NULL
IMMORTALIZATION	NULL
OF	NULL
T	NULL
CELLS	NULL
WITH	NULL
HTLV-1	NULL
Tax	NULL
MUTANTS	NULL
-	NULL
4859	NULL
provided	NULL
by	NULL
O.	NULL
J.	NULL
Semmes	NULL
)	NULL
and	NULL
cotransfected	NULL
with	NULL
the	NULL
HTLV	NULL
LTR-luciferase	NULL
reporter	NULL
construct	NULL
in	NULL
293T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

Positive	NULL
and	NULL
negative	NULL
control	NULL
plasmids	NULL
were	NULL
likewise	NULL
constructed	NULL
by	NULL
PCR	NULL
amplifying	NULL
and	NULL
cloning	NULL
the	NULL
tax	NULL
ORFs	NULL
from	NULL
the	NULL
original	NULL
ACH.pcTax	NULL
and	NULL
ACH.M47	NULL
clones	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
the	NULL
control	NULL
expression	NULL
plasmids	NULL
derived	NULL
from	NULL
the	NULL
original	NULL
ACH.pcTax	NULL
and	NULL
ACH.M47	NULL
clones	NULL
had	NULL
the	NULL
expected	NULL
activity	NULL
with	NULL
respect	NULL
to	NULL
HTLV	NULL
LTR	NULL
activation	NULL
,	NULL
with	NULL
the	NULL
pcTax	NULL
clone	NULL
activating	NULL
the	NULL
LTR	NULL
approximately	NULL
30-fold	NULL
and	NULL
the	NULL
M47	NULL
clone	NULL
having	NULL
<	NULL
10	NULL
%	NULL
of	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
wild-type	NULL
expression	NULL
clone	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
expression	NULL
clones	NULL
derived	NULL
from	NULL
the	NULL
PCR-amplified	NULL
proviral	NULL
tax	NULL
genes	NULL
from	NULL
the	NULL
PCTAX-1	NULL
,	NULL
-2	NULL
,	NULL
and	NULL
-3	NULL
and	NULL
the	NULL
M47-1	NULL
,	NULL
-2	NULL
,	NULL
and	NULL
-3	NULL
cell	NULL
lines	NULL
also	NULL
had	NULL
the	NULL
expected	NULL
activity	NULL
for	NULL
activation	NULL
of	NULL
the	NULL
HTLV	NULL
LTR	NULL
.	NULL

Therefore	NULL
,	NULL
a	NULL
mutation	NULL
had	NULL
not	NULL
occurred	NULL
elsewhere	NULL
in	NULL
the	NULL
tax	NULL
gene	NULL
which	NULL
had	NULL
restored	NULL
the	NULL
ability	NULL
of	NULL
Tax	NULL
to	NULL
activate	NULL
the	NULL
CREB/ATF	NULL
pathway	NULL
.	NULL

Although	NULL
the	NULL
above	NULL
analysis	NULL
rules	NULL
out	NULL
the	NULL
possibility	NULL
of	NULL
a	NULL
reversion	NULL
in	NULL
Tax	NULL
,	NULL
it	NULL
does	NULL
not	NULL
address	NULL
the	NULL
possibility	NULL
of	NULL
a	NULL
cellular	NULL
mutation	NULL
or	NULL
alteration	NULL
in	NULL
cellular	NULL
environment	NULL
which	NULL
results	NULL
in	NULL
an	NULL
increase	NULL
of	NULL
CREB/ATF	NULL
activity	NULL
in	NULL
the	NULL
ACH.M47-immortalized	NULL
cells	NULL
.	NULL

This	NULL
could	NULL
potentially	NULL
be	NULL
due	NULL
to	NULL
an	NULL
increased	NULL
level	NULL
of	NULL
CREB	NULL
expression	NULL
or	NULL
CREB	NULL
phosphorylation	NULL
or	NULL
an	NULL
enhanced	NULL
CREB-CBP-p300	NULL
interaction	NULL
.	NULL

Alternatively	NULL
,	NULL
the	NULL
cells	NULL
immortalized	NULL
with	NULL
the	NULL
ACH.M47	NULL
mutant	NULL
may	NULL
be	NULL
the	NULL
result	NULL
of	NULL
an	NULL
inadvertent	NULL
selection	NULL
for	NULL
cellular	NULL
clones	NULL
which	NULL
express	NULL
abnormally	NULL
high	NULL
levels	NULL
of	NULL
Tax	NULL
,	NULL
thus	NULL
compensating	NULL
for	NULL
the	NULL
lack	NULL
of	NULL
CREB	NULL
activation	NULL
by	NULL
the	NULL
M47	NULL
mutant	NULL
.	NULL

To	NULL
assess	NULL
this	NULL
possibility	NULL
,	NULL
the	NULL
three	NULL
ACH.pcTax-	NULL
and	NULL
ACH.M47-immortalized	NULL
cell	NULL
lines	NULL
were	NULL
directly	NULL
transfected	NULL
by	NULL
electroporation	NULL
with	NULL
the	NULL
HTLV	NULL
LTR-luciferase	NULL
reporter	NULL
construct	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
additionally	NULL
cotransfected	NULL
with	NULL
a	NULL
CMV-CAT	NULL
reporter	NULL
to	NULL
normalize	NULL
for	NULL
transfection	NULL
efficiency	NULL
.	NULL

The	NULL
cell	NULL
lines	NULL
immortalized	NULL
with	NULL
the	NULL
ACH.pcTax	NULL
clone	NULL
all	NULL
had	NULL
higher	NULL
HTLV-1	NULL
LTR	NULL
activity	NULL
than	NULL
the	NULL
ACH.M47-immortalized	NULL
cell	NULL
lines	NULL
,	NULL
which	NULL
expressed	NULL
levels	NULL
of	NULL
luciferase	NULL
similar	NULL
to	NULL
those	NULL
of	NULL
PHA-IL-2-stimulated	NULL
PBMC	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
Western	NULL
immunoblot	NULL
analysis	NULL
indicated	NULL
that	NULL
while	NULL
Tax	NULL
expression	NULL
varied	NULL
among	NULL
the	NULL
cell	NULL
lines	NULL
,	NULL
expression	NULL
of	NULL
Tax	NULL
in	NULL
the	NULL
M47	NULL
cell	NULL
lines	NULL
was	NULL
not	NULL
consistently	NULL
upregulated	NULL
and	NULL
was	NULL
similar	NULL
to	NULL
the	NULL
levels	NULL
in	NULL
the	NULL
PCTAX	NULL
cell	NULL
lines	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
PCTAX	NULL
and	NULL
M47	NULL
cell	NULL
lines	NULL
were	NULL
examined	NULL
for	NULL
activated	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
by	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
analysis	NULL
with	NULL
a	NULL
probe	NULL
containing	NULL
the	NULL
NF-kB	NULL
binding	NULL
site	NULL
from	NULL
the	NULL
IL-Z2Ra	NULL
«	NULL
promoter	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
all	NULL
PCTAX-	NULL
and	NULL
M47-immortalized	NULL
cell	NULL
lines	NULL
had	NULL
increased	NULL
nuclear	NULL
NF-kB	NULL
compared	NULL
to	NULL
activated	NULL
PBMC	NULL
,	NULL
indicating	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
functional	NULL
Tax	NULL
protein	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
these	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
ACH.M47-immortalized	NULL
cells	NULL
do	NULL
not	NULL
have	NULL
abnormally	NULL
altered	NULL
CREB/ATF	NULL
activity	NULL
or	NULL
Tax	NULL
expression	NULL
which	NULL
suppresses	NULL
or	NULL
otherwise	NULL
compensates	NULL
for	NULL
the	NULL
M47	NULL
mutation	NULL
.	NULL

Viral	NULL
replication	NULL
and	NULL
microtiter	NULL
infectivity	NULL
assay	NULL
.	NULL

Despite	NULL
being	NULL
impaired	NULL
for	NULL
replication	NULL
in	NULL
the	NULL
transient	NULL
transfection	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
and	NULL
producing	NULL
lower	NULL
amounts	NULL
of	NULL
virus	NULL
early	NULL
in	NULL
the	NULL
transfection	NULL
of	NULL
PBMC	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
the	NULL
ACH.M47-immortalized	NULL
PBMC	NULL
produce	NULL
virus	NULL
at	NULL
levels	NULL
similar	NULL
to	NULL
ACH	NULL
.	NULL

pcTax-immortalized	NULL
cells	NULL
.	NULL

We	NULL
examined	NULL
whether	NULL
or	NULL
not	NULL
the	NULL
virus	NULL
being	NULL
shed	NULL
from	NULL
the	NULL
ACH.M47-immortalized	NULL
cells	NULL
was	NULL
as	NULL
infectious	NULL
for	NULL
activated	NULL
PBMC	NULL
as	NULL
wild-type	NULL
virus	NULL
.	NULL

One	NULL
ACH	NULL
.	NULL

pcTax-immortalized	NULL
cell	NULL
line	NULL
(	NULL
PCTAX-2	NULL
)	NULL
and	NULL
one	NULL
ACH.M47-immortalized	NULL
cell	NULL
line	NULL
(	NULL
M47-3	NULL
)	NULL
were	NULL
chosen	NULL
that	NULL
expressed	NULL
very	NULL
similar	NULL
amounts	NULL
of	NULL
viral	NULL
particles	NULL
(	NULL
approximately	NULL
500	NULL
pg/	NULL
ml/10®	NULL
cells/24	NULL
h	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
these	NULL
two	NULL
cell	NULL
lines	NULL
were	NULL
both	NULL
derived	NULL
from	NULL
the	NULL
same	NULL
donor	NULL
,	NULL
and	NULL
both	NULL
expressed	NULL
CD4	NULL
on	NULL
their	NULL
surfaces	NULL
(	NULL
although	NULL
M47-3	NULL
also	NULL
expressed	NULL
CD8	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
PCTAX-2	NULL
and	NULL
M47-3	NULL
are	NULL
similar	NULL
in	NULL
many	NULL
respects	NULL
,	NULL
except	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
wild-type	NULL
or	NULL
M47	NULL
mutant	NULL
Tax	NULL
in	NULL
the	NULL
inte-	NULL
4860	NULL
ROBEK	NULL
AND	NULL
RATNER	NULL
CD3	NULL
--	NULL
p	NULL
CD25	NULL
--	NULL
»	NULL
<	NULL
>	NULL
F-	NULL
3	NULL
G	NULL
ab	NULL
)	NULL
e	NULL
[	NULL
an	NULL
c	NULL
3	NULL
€	NULL
-	NULL
£	NULL
&	NULL
aD	NULL
)	NULL
[	NULL
-w	NULL
J.	NULL
Virou	NULL
.	NULL

Counts	NULL
©	NULL
PCTAX-3	NULL
Count	NULL
10°	NULL
qo	NULL
``	NULL
408	NULL
ao	NULL
``	NULL
FL2H	NULL
Counts	NULL
10¢	NULL
40°	NULL
40	NULL
``	NULL
FL2H	NULL
JoqumNn	NULL
[	NULL
[	NULL
3	NULL
)	NULL
sAn2	NULL
]	NULL
9y	NULL
Counts	NULL
Count	NULL
FL2H	NULL
5	NULL
Aor	NULL
in*	NULL
FL14	NULL
10°	NULL
qo	NULL
``	NULL
Relative	NULL
Log	NULL
Fluorescence	NULL
Intensity	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Cell	NULL
surface	NULL
phenotype	NULL
of	NULL
immortalized	NULL
cell	NULL
lines	NULL
.	NULL

ACH.pcTax-	NULL
and	NULL
ACH.M47-immortalized	NULL
cells	NULL
were	NULL
stained	NULL
with	NULL
anti-human	NULL
CD3	NULL
,	NULL
CD25	NULL
,	NULL
CD4	NULL
,	NULL
and	NULL
CD8	NULL
and	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Although	NULL
all	NULL
cell	NULL
lines	NULL
express	NULL
CD3	NULL
and	NULL
CD25	NULL
,	NULL
expression	NULL
of	NULL
CD4	NULL
and	NULL
CD8	NULL
is	NULL
variable	NULL
,	NULL
with	NULL
a	NULL
tendency	NULL
for	NULL
CD4	NULL
expression	NULL
by	NULL
ACH.pcTax-transfected	NULL
cells	NULL
and	NULL
CD8	NULL
expression	NULL
by	NULL
cells	NULL
immortalized	NULL
with	NULL
the	NULL
ACH.M47	NULL
clone	NULL
.	NULL

The	NULL
open	NULL
histogram	NULL
on	NULL
each	NULL
plot	NULL
corresponds	NULL
to	NULL
unstained	NULL
cells	NULL
,	NULL
while	NULL
the	NULL
shaded	NULL
histogram	NULL
corresponds	NULL
to	NULL
cells	NULL
stained	NULL
with	NULL
the	NULL
indicated	NULL
antibody	NULL
.	NULL

grated	NULL
provirus	NULL
.	NULL

Five	NULL
hundred	NULL
thousand	NULL
cells	NULL
were	NULL
lethally	NULL
irradiated	NULL
(	NULL
6,000	NULL
rads	NULL
)	NULL
and	NULL
cocultured	NULL
with	NULL
5	NULL
x	NULL
10°	NULL
PHA-IL-2-activated	NULL
PBMC	NULL
,	NULL
and	NULL
viral	NULL
replication	NULL
was	NULL
monitored	NULL
by	NULL
p19	NULL
ELISA	NULL
on	NULL
cell	NULL
culture	NULL
supernatants	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
the	NULL
virus	NULL
from	NULL
the	NULL
ACH.M47-immortalized	NULL
cells	NULL
replicated	NULL
less	NULL
efficiently	NULL
than	NULL
the	NULL
wild-type	NULL
virus	NULL
due	NULL
to	NULL
the	NULL
inability	NULL
of	NULL
M47	NULL
Tax	NULL
to	NULL
efficiently	NULL
transactivate	NULL
the	NULL
LTR	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

To	NULL
further	NULL
examine	NULL
the	NULL
replication	NULL
and	NULL
immortalizing	NULL
activity	NULL
of	NULL
the	NULL
ACH.M47	NULL
virus	NULL
,	NULL
a	NULL
quantitative	NULL
microtiter	NULL
infectivity	NULL
immortalization	NULL
assay	NULL
was	NULL
employed	NULL
as	NULL
described	NULL
by	NULL
Persaud	NULL
et	NULL
al	NULL
.	NULL

(	NULL
54	NULL
)	NULL
.	NULL

In	NULL
this	NULL
assay	NULL
,	NULL
10°	NULL
PBMC	NULL
were	NULL
cocultured	NULL
with	NULL
10-fold	NULL
dilutions	NULL
(	NULL
10°	NULL
,	NULL
10	NULL
%	NULL
,	NULL
10	NULL
)	NULL
of	NULL
irradiated	NULL
PCTAX-2	NULL
,	NULL
PCTAX-3	NULL
,	NULL
M47-2	NULL
,	NULL
or	NULL
M47-3	NULL
cells	NULL
in	NULL
replicates	NULL
of	NULL
20	NULL
in	NULL
96-well	NULL
microtiter	NULL
plates	NULL
.	NULL

The	NULL
cultures	NULL
were	NULL
examined	NULL
at	NULL
8	NULL
to	NULL
10	NULL
weeks	NULL
postcoculture	NULL
,	NULL
and	NULL
the	NULL
percentage	NULL
of	NULL
cultures	NULL
which	NULL
became	NULL
immortalized	NULL
at	NULL
each	NULL
dilution	NULL
of	NULL
infected	NULL
cells	NULL
was	NULL
quantitated	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

Despite	NULL
being	NULL
less	NULL
able	NULL
to	NULL
replicate	NULL
efficiently	NULL
,	NULL
the	NULL
virus	NULL
from	NULL
the	NULL
M47-2	NULL
and	NULL
M47-3	NULL
cell	NULL
lines	NULL
infected	NULL
and	NULL
im-	NULL
voL	NULL
.	NULL

73	NULL
,	NULL
1999	NULL
1	NULL
-	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
78	NULL
9	NULL
10	NULL
11	NULL
12	NULL
leal	NULL
O	NULL
N	NULL
T	NULL
f	NULL
.	NULL

J	NULL
O	NULL
N	NULL
T	NULL
®	NULL
Fold	NULL
Activation	NULL
®	NULL
E	NULL
&	NULL
x	NULL
«	NULL
[	NULL
an	NULL
9	NULL
C.	NULL
PCTAX-I	NULL
PCTAX-2	NULL
PCTAX-3	NULL
M47-1	NULL
M47-2	NULL
Mm4a7-3	NULL
[	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Lack	NULL
of	NULL
reversion	NULL
of	NULL
M47	NULL
mutation	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
Tax	NULL
ORF	NULL
was	NULL
amplified	NULL
by	NULL
PCR	NULL
from	NULL
genomic	NULL
DNA	NULL
and	NULL
digested	NULL
with	NULL
the	NULL
restriction	NULL
endonuclease	NULL
Bill	NULL
.	NULL

Whereas	NULL
the	NULL
PCR	NULL
products	NULL
from	NULL
all	NULL
three	NULL
ACH.peTax-immortalized	NULL
cell	NULL
lines	NULL
lack	NULL
the	NULL
Bg/lI	NULL
site	NULL
,	NULL
the	NULL
site	NULL
is	NULL
present	NULL
in	NULL
the	NULL
Tax	NULL
fragment	NULL
amplified	NULL
from	NULL
the	NULL
ACH.M47-immortalized	NULL
cells	NULL
.	NULL

Lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
7	NULL
,	NULL
9	NULL
,	NULL
and	NULL
11	NULL
are	NULL
undigested	NULL
(	NULL
u	NULL
)	NULL
,	NULL
while	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
8	NULL
,	NULL
10	NULL
,	NULL
and	NULL
12	NULL
are	NULL
digested	NULL
with	NULL
Bg/II	NULL
(	NULL
c	NULL
[	NULL
cut	NULL
]	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
PCR-amplified	NULL
tax	NULL
genes	NULL
from	NULL
ACH.peTax-	NULL
and	NULL
ACH.M47-immortalized	NULL
cells	NULL
were	NULL
cloned	NULL
into	NULL
a	NULL
CMV	NULL
expression	NULL
vector	NULL
and	NULL
cotransfected	NULL
with	NULL
HTLV-LTR-lucif-erase	NULL
reporter	NULL
construct	NULL
in	NULL
293T	NULL
cells	NULL
.	NULL

As	NULL
positive	NULL
and	NULL
negative	NULL
controls	NULL
,	NULL
the	NULL
wild-type	NULL
and	NULL
M47	NULL
mutant	NULL
tax	NULL
genes	NULL
were	NULL
amplified	NULL
from	NULL
the	NULL
ACH.pcTax	NULL
and	NULL
ACH.M47	NULL
clones	NULL
.	NULL

The	NULL
data	NULL
are	NULL
expressed	NULL
as	NULL
fold	NULL
increase	NULL
in	NULL
luciferase	NULL
activity	NULL
relative	NULL
to	NULL
the	NULL
HTLV	NULL
LTR-luciferase	NULL
construct	NULL
transfected	NULL
alone	NULL
,	NULL
and	NULL
the	NULL
error	NULL
bars	NULL
represent	NULL
the	NULL
standard	NULL
deviations	NULL
of	NULL
four	NULL
replicate	NULL
transfections	NULL
.	NULL

mortalized	NULL
the	NULL
uninfected	NULL
PBMC	NULL
at	NULL
each	NULL
dilution	NULL
of	NULL
infected	NULL
cells	NULL
at	NULL
a	NULL
rate	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
the	NULL
PCTAX-2-	NULL
and	NULL
PCTAX-3-derived	NULL
virus	NULL
.	NULL

Thus	NULL
,	NULL
there	NULL
does	NULL
not	NULL
seem	NULL
to	NULL
be	NULL
a	NULL
quantitative	NULL
difference	NULL
in	NULL
the	NULL
immortalizing	NULL
activity	NULL
of	NULL
the	NULL
M47	NULL
mutant	NULL
Tax	NULL
.	NULL

Cell	NULL
surface	NULL
phenotype	NULL
of	NULL
immortalized	NULL
cell	NULL
lines	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
cells	NULL
immortalized	NULL
by	NULL
transfection	NULL
of	NULL
PBMC	NULL
by	NULL
the	NULL
ACH.pcTax	NULL
and	NULL
ACH.M47	NULL
proviral	NULL
clones	NULL
revealed	NULL
that	NULL
while	NULL
all	NULL
cell	NULL
lines	NULL
were	NULL
activated	NULL
T	NULL
cells	NULL
,	NULL
expression	NULL
of	NULL
CD4	NULL
and	NULL
CD8	NULL
varied	NULL
,	NULL
with	NULL
a	NULL
slight	NULL
bias	NULL
for	NULL
CD4	NULL
expression	NULL
by	NULL
ACH.pcTax-immortalized	NULL
cells	NULL
and	NULL
for	NULL
CD8	NULL
expression	NULL
by	NULL
ACH.M47-immortalized	NULL
cells	NULL
.	NULL

To	NULL
examine	NULL
this	NULL
phenomenon	NULL
further	NULL
,	NULL
12	NULL
IMMORTALIZATION	NULL
OF	NULL
T	NULL
CELLS	NULL
WITH	NULL
HTLV-1	NULL
Tax	NULL
MUTANTS	NULL
_	NULL
4861	NULL
£	NULL
2	NULL
C	NULL
3.9	NULL
$	NULL
$	NULL
2	NULL
o	NULL
'T	NULL
«	NULL
o	NULL
EB	NULL
o	NULL
12	NULL
2	NULL
-	NULL
]	NULL
34	NULL
c	NULL
L_	NULL
.	NULL

_	NULL
Xoo	NULL
Xo0	NULL
Ko	NULL
om	NULL
-m	NULL
-m	NULL
tto	NULL
o	NULL
oth	NULL
o	NULL
os	NULL
§	NULL
Ao	NULL
fo	NULL
§	NULL
%	NULL
%	NULL
&	NULL
Qo	NULL
Q	NULL
-	NULL
Q	NULL
A	NULL
0	NULL
A	NULL
=	NULL
=	NULL
A	NULL
10g	NULL
z	NULL
mom	NULL
y	NULL
a	NULL
a	NULL
do	NULL
1	NULL
CT	NULL
92	NULL
¥	NULL
a	NULL
Eo	NULL
Rf	NULL
oR	NULL
g	NULL
got	NULL
&	NULL
2	NULL
J	NULL
Q	NULL
O	NULL
%	NULL
o	NULL
m	NULL
E	NULL
mmmEEEc-E47	NULL
Tir-p	NULL
%	NULL
s	NULL
a-	NULL
.	NULL

--	NULL
a*	NULL
G	NULL
#	NULL
a-	NULL
€	NULL
)	NULL
~	NULL
w=	NULL
33	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Activation	NULL
of	NULL
HTLV-1	NULL
LTR	NULL
and	NULL
Tax	NULL
expression	NULL
in	NULL
immortalized	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
ACH.pcTax-	NULL
and	NULL
ACH.M47-immortalized	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
20	NULL
wg	NULL
of	NULL
HTLV	NULL
LTR-luciferase	NULL
and	NULL
5	NULL
ug	NULL
of	NULL
CMV-CAT	NULL
.	NULL

Luciferase	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
30	NULL
pg	NULL
of	NULL
whole-cell	NULL
extract	NULL
,	NULL
and	NULL
CAT	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
3	NULL
ug	NULL
of	NULL
extract	NULL
.	NULL

The	NULL
data	NULL
are	NULL
expressed	NULL
as	NULL
relative	NULL
light	NULL
units	NULL
per	NULL
1	NULL
%	NULL
conversion	NULL
CAT	NULL
activity	NULL
.	NULL

The	NULL
error	NULL
bars	NULL
indicate	NULL
the	NULL
standard	NULL
deviations	NULL
of	NULL
three	NULL
replicate	NULL
transfections	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Tax	NULL
expression	NULL
in	NULL
whole-cell	NULL
extracts	NULL
prepared	NULL
from	NULL
PCTAX	NULL
and	NULL
M47	NULL
cell	NULL
lines	NULL
.	NULL

For	NULL
negative	NULL
and	NULL
positive	NULL
controls	NULL
.	NULL

Tax	NULL
expression	NULL
was	NULL
also	NULL
examined	NULL
in	NULL
PHA-IL-2-stimulated	NULL
PBMC	NULL
and	NULL
the	NULL
HTLV-1-infected	NULL
cell	NULL
line	NULL
MT-2	NULL
.	NULL

ACH.pcTax	NULL
and	NULL
12	NULL
ACH.M47	NULL
cell	NULL
lines	NULL
produced	NULL
during	NULL
the	NULL
course	NULL
of	NULL
the	NULL
microtiter	NULL
infectivity	NULL
assay	NULL
were	NULL
examined	NULL
for	NULL
cell	NULL
surface	NULL
marker	NULL
expression	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

As	NULL
was	NULL
observed	NULL
for	NULL
the	NULL
ACH	NULL
-transfected	NULL
PBMC	NULL
,	NULL
the	NULL
immortalized	NULL
cell	NULL
lines	NULL
derived	NULL
from	NULL
infection	NULL
with	NULL
the	NULL
M47-2-	NULL
or	NULL
M47-3-derived	NULL
virus	NULL
were	NULL
more	NULL
likely	NULL
to	NULL
be	NULL
either	NULL
CD8*	NULL
T	NULL
cells	NULL
or	NULL
mixed	NULL
cultures	NULL
of	NULL
CD4	NULL
*	NULL
and	NULL
CD8	NULL
*	NULL
cells	NULL
.	NULL

Likewise	NULL
,	NULL
the	NULL
cultures	NULL
infected	NULL
with	NULL
the	NULL
PCTAX-2-	NULL
or	NULL
PCTAX-3-derived	NULL
virus	NULL
were	NULL
more	NULL
likely	NULL
to	NULL
be	NULL
CD4*	NULL
T	NULL
lymphocytes	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
activation	NULL
of	NULL
the	NULL
CREB/ATF	NULL
pathway	NULL
by	NULL
Tax	NULL
may	NULL
be	NULL
important	NULL
for	NULL
the	NULL
preferential	NULL
immortalization	NULL
of	NULL
CD4	NULL
*	NULL
cells	NULL
compared	NULL
to	NULL
that	NULL
of	NULL
CD8*	NULL
cells	NULL
by	NULL
HTLV-1	NULL
,	NULL
despite	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
virus	NULL
can	NULL
infect	NULL
both	NULL
types	NULL
of	NULL
cells	NULL
.	NULL

DISCUSSION	NULL
The	NULL
Tax	NULL
protein	NULL
of	NULL
HTLV-1	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
have	NULL
a	NULL
number	NULL
of	NULL
activities	NULL
which	NULL
may	NULL
all	NULL
lead	NULL
directly	NULL
or	NULL
indirectly	NULL
4862	NULL
,	NULL
ROBEK	NULL
AND	NULL
RATNER	NULL
A	NULL
20,000	NULL
7	NULL
15,000	NULL
+	NULL
APCTAX-2	NULL
O	NULL
M47-3	NULL
10,000	NULL
+	NULL
p19	NULL
Antigen	NULL
(	NULL
pg/ml	NULL
)	NULL
3	NULL
7	NULL
10	NULL
18	NULL
Days	NULL
Post	NULL
Infection	NULL
%	NULL
Cultures	NULL
Immortalized	NULL
M47-2	NULL
M47-3	NULL
»	NULL
<	NULL
.	NULL

@	NULL
A	NULL
.	NULL

FIG	NULL
.	NULL

7	NULL
.	NULL

Replication	NULL
and	NULL
immortalization	NULL
by	NULL
ACH.M47	NULL
virus	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Five	NULL
hundred	NULL
thousand	NULL
PCTAX-2-	NULL
or	NULL
M47-3-immortalized	NULL
cells	NULL
were	NULL
lethally	NULL
gamma	NULL
irradiated	NULL
(	NULL
6,000	NULL
rads	NULL
)	NULL
and	NULL
cocultured	NULL
with	NULL
5	NULL
X	NULL
10°	NULL
PHA-activated	NULL
uninfected	NULL
PBMC	NULL
.	NULL

Viral	NULL
replication	NULL
was	NULL
determined	NULL
by	NULL
p19	NULL
antigen	NULL
ELISA	NULL
.	NULL

The	NULL
standard	NULL
deviation	NULL
of	NULL
two	NULL
replicate	NULL
infections	NULL
is	NULL
indicated	NULL
by	NULL
the	NULL
error	NULL
bars	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Results	NULL
of	NULL
microtiter	NULL
infectivity-immortalization	NULL
assay	NULL
.	NULL

Ten	NULL
thousand	NULL
PHA-IL-2-activated	NULL
PBMC	NULL
were	NULL
cocultured	NULL
with	NULL
10°	NULL
,	NULL
10	NULL
%	NULL
,	NULL
or	NULL
10	NULL
gamma-irradiated	NULL
PCTAX-2-	NULL
,	NULL
PCTAX-3-	NULL
,	NULL
M47-2-	NULL
,	NULL
or	NULL
M47-3-immortalized	NULL
cells	NULL
in	NULL
replicates	NULL
of	NULL
20	NULL
in	NULL
96-well	NULL
plates	NULL
.	NULL

The	NULL
cultures	NULL
were	NULL
examined	NULL
at	NULL
8	NULL
weeks	NULL
postcoculture	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
viable	NULL
cells	NULL
,	NULL
and	NULL
the	NULL
number	NULL
of	NULL
cultures	NULL
which	NULL
were	NULL
immortalized	NULL
at	NULL
each	NULL
dilution	NULL
was	NULL
determined	NULL
.	NULL

to	NULL
cellular	NULL
immortalization	NULL
and	NULL
transformation	NULL
of	NULL
the	NULL
infected	NULL
cell	NULL
.	NULL

Tax	NULL
interacts	NULL
with	NULL
the	NULL
mitotic	NULL
checkpoint	NULL
protein	NULL
MAD1	NULL
,	NULL
and	NULL
this	NULL
interaction	NULL
leads	NULL
to	NULL
the	NULL
loss	NULL
of	NULL
MAD1	NULL
function	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Tax	NULL
also	NULL
interacts	NULL
with	NULL
Cdk4	NULL
and	NULL
Cdk6	NULL
and	NULL
increases	NULL
their	NULL
activities	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
65	NULL
)	NULL
.	NULL

Tax	NULL
has	NULL
also	NULL
been	NULL
shown	NULL
to	NULL
interact	NULL
with	NULL
and	NULL
inactivate	NULL
the	NULL
Cdk	NULL
inhibitor	NULL
pl6INK4a	NULL
(	NULL
41	NULL
,	NULL
72	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
Tax	NULL
functionally	NULL
inactivates	NULL
p53	NULL
through	NULL
an	NULL
increase	NULL
in	NULL
phosphorylation	NULL
,	NULL
although	NULL
the	NULL
mechanistic	NULL
details	NULL
are	NULL
still	NULL
unclear	NULL
(	NULL
46	NULL
,	NULL
55	NULL
,	NULL
56	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
expression	NULL
of	NULL
Tax	NULL
leads	NULL
to	NULL
DNA	NULL
damage	NULL
,	NULL
which	NULL
may	NULL
be	NULL
associated	NULL
with	NULL
the	NULL
transcriptional	NULL
repression	NULL
of	NULL
DNA	NULL
polymerase-B	NULL
(	NULL
29	NULL
)	NULL
and/or	NULL
increased	NULL
PCNA	NULL
expression	NULL
(	NULL
58	NULL
)	NULL
.	NULL

J.	NULL
Virou	NULL
.	NULL

TABLE	NULL
2	NULL
.	NULL

Cell	NULL
surface	NULL
phenotype	NULL
of	NULL
immortalized	NULL
PBMC	NULL
from	NULL
transfections	NULL
and	NULL
infections	NULL
No	NULL
.	NULL

of	NULL
cultures	NULL
with	NULL
phenotype/total	NULL
cultures	NULL
Status	NULL
-	NULL
and	NULL
clone	NULL
-	NULL
ory4-	NULL
cp§-	NULL
CD4*	NULL
CD8	NULL
``	NULL
CD4~-	NULL
CD8**	NULL
Mmé	NULL
‘	NULL
lggP	NULL
“	NULL
Transfected	NULL
``	NULL
ACH	NULL
.	NULL

wt	NULL
oM	NULL
aja	NULL
0/4	NULL
e	NULL
ACH.pcTax	NULL
1/4	NULL
3/4	NULL
0/4	NULL
0/4	NULL
ACH.M47	NULL
0/5	NULL
1/5	NULL
2/5	NULL
2/5	NULL
Infected	NULL
``	NULL
PCTAX-2	NULL
0/6	NULL
6/6	NULL
0/6	NULL
0/6	NULL
PCTAX-3	NULL
0/6	NULL
3/6	NULL
0/6	NULL
3/6	NULL
M47-2	NULL
0/6	NULL
0/6	NULL
3/6	NULL
3/6	NULL
M47-3	NULL
0/6	NULL
0/6	NULL
2/6	NULL
4/6	NULL
``	NULL
Immortalized	NULL
cell	NULL
cultures	NULL
which	NULL
were	NULL
derived	NULL
from	NULL
electroporation	NULL
of	NULL
PBMC	NULL
with	NULL
ACH	NULL
molecular	NULL
clones	NULL
.	NULL

The	NULL
tabulation	NULL
includes	NULL
the	NULL
data	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

®	NULL
Immortalized	NULL
cell	NULL
cultures	NULL
created	NULL
from	NULL
microtiter	NULL
infectivity-immortalization	NULL
assay	NULL
.	NULL

°	NULL
Cultures	NULL
were	NULL
considered	NULL
to	NULL
be	NULL
CD4*	NULL
CD8~	NULL
or	NULL
CD4~	NULL
CD8	NULL
``	NULL
if	NULL
>	NULL
90	NULL
%	NULL
of	NULL
cells	NULL
expressed	NULL
CD4	NULL
or	NULL
CD8	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
Tax	NULL
to	NULL
upregulate	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
genes	NULL
involved	NULL
in	NULL
cellular	NULL
proliferation	NULL
or	NULL
cell	NULL
cycle	NULL
control	NULL
has	NULL
also	NULL
been	NULL
proposed	NULL
as	NULL
contributing	NULL
to	NULL
the	NULL
ability	NULL
of	NULL
Tax	NULL
to	NULL
transform	NULL
cells	NULL
.	NULL

Among	NULL
the	NULL
genes	NULL
demonstrated	NULL
to	NULL
be	NULL
upregulated	NULL
by	NULL
Tax	NULL
are	NULL
c-fos	NULL
and	NULL
the	NULL
genes	NULL
for	NULL
PCNA	NULL
,	NULL
platelet-de-rived	NULL
growth	NULL
factor	NULL
(	NULL
c-sis	NULL
)	NULL
,	NULL
IL-2	NULL
,	NULL
and	NULL
IL-2Ra	NULL
(	NULL
3	NULL
,	NULL
14	NULL
,	NULL
25	NULL
,	NULL
40	NULL
,	NULL
58	NULL
,	NULL
68	NULL
,	NULL
75	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
Tax	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
repress	NULL
the	NULL
transcription	NULL
of	NULL
p53	NULL
(	NULL
76	NULL
)	NULL
and	NULL
bex	NULL
(	NULL
9	NULL
)	NULL
,	NULL
which	NULL
may	NULL
lead	NULL
to	NULL
an	NULL
inhibition	NULL
of	NULL
apoptosis	NULL
in	NULL
the	NULL
infected	NULL
cell	NULL
.	NULL

Tax	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
have	NULL
transforming	NULL
activity	NULL
in	NULL
a	NULL
number	NULL
of	NULL
cell	NULL
culture	NULL
systems	NULL
(	NULL
2	NULL
,	NULL
17	NULL
,	NULL
43	NULL
,	NULL
62	NULL
,	NULL
63	NULL
,	NULL
70	NULL
,	NULL
78	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
relative	NULL
importance	NULL
of	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
CREB/ATF	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
pathways	NULL
for	NULL
transforming	NULL
activity	NULL
is	NULL
controversial	NULL
.	NULL

Studies	NULL
examining	NULL
the	NULL
transformation	NULL
of	NULL
established	NULL
rodent	NULL
cell	NULL
lines	NULL
have	NULL
produced	NULL
conflicting	NULL
results	NULL
.	NULL

Smith	NULL
and	NULL
Greene	NULL
examined	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
M22	NULL
and	NULL
M47	NULL
mutations	NULL
to	NULL
transform	NULL
Rat2	NULL
fibroblasts	NULL
and	NULL
determined	NULL
that	NULL
the	NULL
CREB	NULL
pathway	NULL
is	NULL
important	NULL
for	NULL
transformation	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
M47	NULL
was	NULL
defective	NULL
for	NULL
cellular	NULL
transformation	NULL
,	NULL
while	NULL
M22	NULL
retained	NULL
transforming	NULL
activity	NULL
)	NULL
(	NULL
70	NULL
)	NULL
.	NULL

However	NULL
,	NULL
subsequently	NULL
Yamaoka	NULL
et	NULL
al	NULL
.	NULL

and	NULL
Matsumoto	NULL
et	NULL
al	NULL
.	NULL

have	NULL
demonstrated	NULL
that	NULL
the	NULL
NF-kB	NULL
pathway	NULL
appears	NULL
to	NULL
be	NULL
important	NULL
for	NULL
the	NULL
transformation	NULL
of	NULL
Ratl	NULL
fibroblasts	NULL
(	NULL
43	NULL
,	NULL
78	NULL
)	NULL
.	NULL

Studies	NULL
utilizing	NULL
viral	NULL
transduction	NULL
systems	NULL
to	NULL
evaluate	NULL
the	NULL
ability	NULL
of	NULL
Tax	NULL
mutants	NULL
to	NULL
immortalize	NULL
primary	NULL
human	NULL
PBMC	NULL
have	NULL
also	NULL
produced	NULL
varied	NULL
results	NULL
.	NULL

Rosin	NULL
et	NULL
al	NULL
.	NULL

demonstrated	NULL
that	NULL
a	NULL
Tax	NULL
point	NULL
mutation	NULL
defective	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
induction	NULL
(	NULL
S258A	NULL
)	NULL
retains	NULL
the	NULL
capability	NULL
to	NULL
immortalize	NULL
primary	NULL
lymphocytes	NULL
when	NULL
transduced	NULL
by	NULL
a	NULL
herpesvirus	NULL
saimiri	NULL
vector	NULL
(	NULL
62	NULL
)	NULL
.	NULL

On	NULL
the	NULL
contrary	NULL
,	NULL
Akagi	NULL
et	NULL
al	NULL
.	NULL

demonstrated	NULL
that	NULL
the	NULL
M22	NULL
Tax	NULL
mutation	NULL
fails	NULL
to	NULL
immortalize	NULL
PBMC	NULL
when	NULL
transduced	NULL
by	NULL
a	NULL
retroviral	NULL
expression	NULL
vector	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
antisense	NULL
oligonucleotides	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
can	NULL
inhibit	NULL
the	NULL
proliferation	NULL
of	NULL
Tax-transformed	NULL
tumors	NULL
from	NULL
Tax-transgenic	NULL
mice	NULL
(	NULL
36	NULL
)	NULL
.	NULL

The	NULL
apparent	NULL
discrepancies	NULL
among	NULL
these	NULL
results	NULL
are	NULL
likely	NULL
due	NULL
to	NULL
a	NULL
number	NULL
of	NULL
factors	NULL
,	NULL
including	NULL
differences	NULL
in	NULL
the	NULL
experimental	NULL
systems	NULL
utilized	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
rodent	NULL
fibroblasts	NULL
versus	NULL
human	NULL
primary	NULL
PBMC	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
subtle	NULL
differences	NULL
in	NULL
the	NULL
activities	NULL
of	NULL
the	NULL
mutants	NULL
used	NULL
(	NULL
NF-kB	NULL
mutations	NULL
M22	NULL
,	NULL
$	NULL
258	NULL
,	NULL
and	NULL
G148V	NULL
)	NULL
and	NULL
the	NULL
levels	NULL
of	NULL
Tax	NULL
expression	NULL
may	NULL
also	NULL
account	NULL
for	NULL
differences	NULL
in	NULL
the	NULL
observed	NULL
phenotypes	NULL
.	NULL

None	NULL
of	NULL
these	NULL
studies	NULL
,	NULL
however	NULL
,	NULL
examined	NULL
the	NULL
role	NULL
of	NULL
Tax	NULL
in	NULL
immortalization	NULL
or	NULL
transformation	NULL
in	NULL
the	NULL
context	NULL
of	NULL
a	NULL
replicating	NULL
HTLV-1	NULL
virus	NULL
in	NULL
voL	NULL
.	NULL

73	NULL
,	NULL
1999	NULL
primary	NULL
PBMC	NULL
,	NULL
which	NULL
may	NULL
be	NULL
the	NULL
closest	NULL
model	NULL
of	NULL
what	NULL
occurs	NULL
in	NULL
vivo	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
NF-kB	NULL
pathway	NULL
by	NULL
Tax	NULL
is	NULL
critical	NULL
for	NULL
the	NULL
immortalization	NULL
of	NULL
PBMC	NULL
by	NULL
HTLV-1	NULL
.	NULL

Disregulated	NULL
activity	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
be	NULL
transforming	NULL
and	NULL
associated	NULL
with	NULL
other	NULL
human	NULL
cancers	NULL
.	NULL

The	NULL
IxB	NULL
family	NULL
member	NULL
be/-3	NULL
is	NULL
located	NULL
at	NULL
a	NULL
site	NULL
of	NULL
chromosomal	NULL
translocations	NULL
in	NULL
a	NULL
specific	NULL
type	NULL
of	NULL
B-cell	NULL
leukemia	NULL
(	NULL
51	NULL
)	NULL
.	NULL

Likewise	NULL
,	NULL
the	NULL
NF-kB	NULL
family	NULL
member	NULL
p52	NULL
was	NULL
identified	NULL
in	NULL
the	NULL
cloning	NULL
of	NULL
a	NULL
chromosomal	NULL
translocation	NULL
in	NULL
a	NULL
non-Hodgkin	NULL
's	NULL
B-cell	NULL
lymphoma	NULL
(	NULL
48	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
LMP-1	NULL
protein	NULL
activates	NULL
the	NULL
NF-kB	NULL
pathway	NULL
by	NULL
interaction	NULL
with	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
(	NULL
TNFR	NULL
)	NULL
-associated	NULL
factors	NULL
(	NULL
TRAFs	NULL
)	NULL
and	NULL
the	NULL
TNFR-associated	NULL
death	NULL
domain	NULL
protein	NULL
(	NULL
TRADD	NULL
)	NULL
through	NULL
a	NULL
pathway	NULL
that	NULL
involves	NULL
NIK	NULL
,	NULL
IKK	NULL
,	NULL
and	NULL
IKKS	NULL
(	NULL
18	NULL
,	NULL
73	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
activation	NULL
of	NULL
NF-kB	NULL
by	NULL
LMP	NULL
through	NULL
its	NULL
interactions	NULL
with	NULL
the	NULL
TRAFs	NULL
and	NULL
TRADD	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
be	NULL
important	NULL
for	NULL
its	NULL
B-lymphocyte	NULL
growth-transforming	NULL
activity	NULL
(	NULL
12	NULL
,	NULL
28	NULL
)	NULL
.	NULL

As	NULL
mentioned	NULL
previously	NULL
,	NULL
the	NULL
M22	NULL
Tax	NULL
mutant	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
lack	NULL
NF-	NULL
activity	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
cell	NULL
types	NULL
,	NULL
including	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
69	NULL
)	NULL
and	NULL
primary	NULL
human	NULL
PBMC	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
M22	NULL
Tax	NULL
fails	NULL
to	NULL
activate	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
a	NULL
defect	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IKK-acti-vating	NULL
kinases	NULL
MEKK1	NULL
and	NULL
NIK	NULL
(	NULL
15	NULL
,	NULL
79	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
M22	NULL
mutation	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
is	NULL
clear	NULL
,	NULL
other	NULL
effects	NULL
that	NULL
the	NULL
M22	NULL
mutation	NULL
may	NULL
have	NULL
on	NULL
other	NULL
Tax	NULL
functions	NULL
is	NULL
less	NULL
well	NULL
established	NULL
.	NULL

For	NULL
example	NULL
,	NULL
Pise-Masison	NULL
et	NULL
al	NULL
.	NULL

have	NULL
demonstrated	NULL
that	NULL
M22	NULL
mutant	NULL
Tax	NULL
is	NULL
not	NULL
able	NULL
to	NULL
functionally	NULL
inactivate	NULL
p53	NULL
as	NULL
wild-type	NULL
Tax	NULL
is	NULL
capable	NULL
of	NULL
doing	NULL
(	NULL
55	NULL
)	NULL
.	NULL

However	NULL
,	NULL
Mulloy	NULL
et	NULL
al	NULL
.	NULL

have	NULL
shown	NULL
that	NULL
M22	NULL
retains	NULL
the	NULL
ability	NULL
to	NULL
inactivate	NULL
p53	NULL
function	NULL
(	NULL
46	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
M22	NULL
mutant	NULL
Tax	NULL
protein	NULL
does	NULL
not	NULL
dimerize	NULL
as	NULL
efficiently	NULL
as	NULL
wild-type	NULL
Tax	NULL
(	NULL
74	NULL
)	NULL
,	NULL
which	NULL
may	NULL
also	NULL
influence	NULL
various	NULL
Tax	NULL
activities	NULL
,	NULL
including	NULL
HTLV	NULL
LTR	NULL
activation	NULL
(	NULL
1	NULL
,	NULL
81	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
can	NULL
not	NULL
rigorously	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
lack	NULL
of	NULL
immortalizing	NULL
activity	NULL
observed	NULL
with	NULL
the	NULL
ACH.M22	NULL
clone	NULL
may	NULL
be	NULL
due	NULL
to	NULL
a	NULL
defect	NULL
in	NULL
Tax	NULL
to	NULL
interact	NULL
with	NULL
or	NULL
activate	NULL
or	NULL
inactivate	NULL
some	NULL
additional	NULL
factor	NULL
.	NULL

Examination	NULL
of	NULL
additional	NULL
Tax	NULL
mutants	NULL
defective	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
induction	NULL
may	NULL
help	NULL
to	NULL
conclusively	NULL
define	NULL
a	NULL
role	NULL
for	NULL
NF-kB	NULL
induction	NULL
in	NULL
HTLV-1-mediated	NULL
cellular	NULL
immortalization	NULL
.	NULL

Our	NULL
results	NULL
also	NULL
indicate	NULL
that	NULL
activation	NULL
of	NULL
the	NULL
CREB/ATF	NULL
pathway	NULL
by	NULL
Tax	NULL
is	NULL
not	NULL
necessary	NULL
for	NULL
immortalization	NULL
.	NULL

This	NULL
is	NULL
somewhat	NULL
surprising	NULL
,	NULL
as	NULL
the	NULL
ACH.M47-derived	NULL
virus	NULL
replicates	NULL
to	NULL
much	NULL
lower	NULL
levels	NULL
than	NULL
the	NULL
wild-type	NULL
ACH.pcTax-derived	NULL
virus	NULL
,	NULL
due	NULL
to	NULL
the	NULL
defect	NULL
in	NULL
CREB	NULL
activation	NULL
.	NULL

However	NULL
,	NULL
the	NULL
ACH.M47-immortalized	NULL
cells	NULL
produce	NULL
viral	NULL
particles	NULL
to	NULL
levels	NULL
similar	NULL
to	NULL
those	NULL
of	NULL
ACH.pcTax-immortalized	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

There	NULL
are	NULL
a	NULL
number	NULL
of	NULL
possible	NULL
explanations	NULL
for	NULL
this	NULL
observation	NULL
.	NULL

The	NULL
possibility	NULL
exists	NULL
that	NULL
once	NULL
the	NULL
cells	NULL
become	NULL
immortalized	NULL
,	NULL
there	NULL
are	NULL
sufficient	NULL
levels	NULL
of	NULL
CREB	NULL
or	NULL
other	NULL
transcription	NULL
factors	NULL
to	NULL
drive	NULL
levels	NULL
of	NULL
viral	NULL
gene	NULL
expression	NULL
that	NULL
lead	NULL
to	NULL
relatively	NULL
large	NULL
amounts	NULL
of	NULL
viral	NULL
particle	NULL
production	NULL
.	NULL

Second	NULL
,	NULL
regulation	NULL
of	NULL
viral	NULL
gene	NULL
expression	NULL
in	NULL
the	NULL
immortalized	NULL
cell	NULL
may	NULL
be	NULL
more	NULL
complex	NULL
than	NULL
simple	NULL
activation	NULL
of	NULL
the	NULL
LTR	NULL
by	NULL
Tax	NULL
,	NULL
as	NULL
a	NULL
number	NULL
of	NULL
studies	NULL
have	NULL
identified	NULL
suppressors	NULL
of	NULL
the	NULL
LTR	NULL
,	NULL
possibly	NULL
in	NULL
the	NULL
R	NULL
and	NULL
US	NULL
regions	NULL
(	NULL
52	NULL
,	NULL
77	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
expression	NULL
of	NULL
viral	NULL
genes	NULL
by	NULL
the	NULL
ACH	NULL
clone	NULL
appears	NULL
to	NULL
be	NULL
restricted	NULL
in	NULL
lymphoid	NULL
cell	NULL
lines	NULL
but	NULL
not	NULL
in	NULL
primary	NULL
PBMC	NULL
(	NULL
34	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
fact	NULL
that	NULL
CREB	NULL
activation	NULL
is	NULL
not	NULL
necessary	NULL
for	NULL
immortalization	NULL
may	NULL
not	NULL
be	NULL
surprising	NULL
,	NULL
in	NULL
that	NULL
few	NULL
cellular	NULL
genes	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
activated	NULL
by	NULL
Tax	NULL
through	NULL
the	NULL
CREB/ATF	NULL
pathway	NULL
.	NULL

However	NULL
,	NULL
though	NULL
activation	NULL
of	NULL
the	NULL
CREB/ATF	NULL
pathway	NULL
is	NULL
dispensable	NULL
for	NULL
cellular	NULL
immortalization	NULL
(	NULL
IL-2-dependent	NULL
growth	NULL
)	NULL
,	NULL
our	NULL
results	NULL
do	NULL
not	NULL
rule	NULL
out	NULL
the	NULL
IMMORTALIZATION	NULL
OF	NULL
T	NULL
CELLS	NULL
WITH	NULL
HTLV-1	NULL
Tax	NULL
MUTANTS	NULL
-	NULL
4863	NULL
possibility	NULL
that	NULL
Tax	NULL
interaction	NULL
with	NULL
the	NULL
CREB/ATF	NULL
pathway	NULL
is	NULL
important	NULL
for	NULL
the	NULL
emergence	NULL
of	NULL
fully	NULL
transformed	NULL
cells	NULL
which	NULL
proliferate	NULL
independently	NULL
of	NULL
IL-2	NULL
.	NULL

In	NULL
vivo	NULL
,	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
represent	NULL
the	NULL
major	NULL
infected	NULL
cell	NULL
type	NULL
in	NULL
asymptomatic	NULL
individuals	NULL
(	NULL
59	NULL
,	NULL
60	NULL
)	NULL
,	NULL
and	NULL
the	NULL
leukemic	NULL
cells	NULL
in	NULL
patients	NULL
with	NULL
adult	NULL
T-cell	NULL
leukemia/lymphoma	NULL
are	NULL
CD4*	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
majority	NULL
of	NULL
cases	NULL
(	NULL
21	NULL
,	NULL
31	NULL
,	NULL
33	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
,	NULL
HTLV-1	NULL
can	NULL
infect	NULL
and	NULL
immortalize	NULL
CD4	NULL
*	NULL
as	NULL
well	NULL
as	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
although	NULL
immortalization	NULL
and	NULL
transformation	NULL
of	NULL
CD4	NULL
*	NULL
cells	NULL
is	NULL
more	NULL
common	NULL
(	NULL
42	NULL
,	NULL
54	NULL
)	NULL
.	NULL

While	NULL
the	NULL
M47	NULL
mutant	NULL
virus	NULL
retains	NULL
the	NULL
ability	NULL
to	NULL
immortalize	NULL
infected	NULL
T	NULL
cells	NULL
,	NULL
there	NULL
appears	NULL
to	NULL
be	NULL
a	NULL
difference	NULL
in	NULL
the	NULL
phenotype	NULL
of	NULL
the	NULL
immortalized	NULL
cells	NULL
,	NULL
as	NULL
CD8	NULL
*	NULL
cells	NULL
become	NULL
immortalized	NULL
at	NULL
a	NULL
much	NULL
higher	NULL
frequency	NULL
than	NULL
that	NULL
observed	NULL
with	NULL
the	NULL
wild-type	NULL
virus	NULL
.	NULL

Newbound	NULL
et	NULL
al	NULL
.	NULL

have	NULL
demonstrated	NULL
that	NULL
the	NULL
ability	NULL
of	NULL
Tax	NULL
to	NULL
activate	NULL
the	NULL
HTLV-1	NULL
LTR	NULL
is	NULL
greatly	NULL
enhanced	NULL
in	NULL
CD4*	NULL
cells	NULL
compared	NULL
to	NULL
CD8	NULL
~*	NULL
cells	NULL
(	NULL
50	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
it	NULL
was	NULL
proposed	NULL
that	NULL
this	NULL
difference	NULL
may	NULL
account	NULL
for	NULL
the	NULL
higher	NULL
frequency	NULL
of	NULL
CD4~	NULL
HTLV-1-im-mortalized	NULL
cells	NULL
than	NULL
CD8	NULL
*	NULL
immortalized	NULL
cells	NULL
(	NULL
50	NULL
)	NULL
.	NULL

This	NULL
hypothesis	NULL
is	NULL
consistent	NULL
with	NULL
our	NULL
findings	NULL
.	NULL

Since	NULL
the	NULL
virus	NULL
with	NULL
the	NULL
M47	NULL
mutation	NULL
does	NULL
not	NULL
efficiently	NULL
transactivate	NULL
the	NULL
LTR	NULL
,	NULL
there	NULL
would	NULL
be	NULL
no	NULL
selective	NULL
advantage	NULL
for	NULL
replication	NULL
in	NULL
CD4	NULL
*	NULL
cells	NULL
versus	NULL
CD8	NULL
*	NULL
cells	NULL
.	NULL

Therefore	NULL
,	NULL
one	NULL
would	NULL
expect	NULL
an	NULL
approximately	NULL
equal	NULL
frequency	NULL
of	NULL
CD4	NULL
*	NULL
and	NULL
CD8	NULL
*	NULL
immortalized	NULL
cells	NULL
with	NULL
the	NULL
M47	NULL
mutant	NULL
virus	NULL
.	NULL

Alternatively	NULL
,	NULL
activation	NULL
of	NULL
the	NULL
CREB/ATF	NULL
pathway	NULL
may	NULL
be	NULL
important	NULL
for	NULL
increased	NULL
proliferation	NULL
and	NULL
outgrowth	NULL
of	NULL
CD4	NULL
*	NULL
cells	NULL
,	NULL
as	NULL
was	NULL
proposed	NULL
by	NULL
Akagi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
who	NULL
observed	NULL
immortalization	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
by	NULL
ret-rovirally	NULL
transduced	NULL
wild-type	NULL
Tax	NULL
and	NULL
CD8	NULL
*	NULL
cells	NULL
by	NULL
transduced	NULL
M47	NULL
mutant	NULL
Tax	NULL
(	NULL
2	NULL
)	NULL
.	NULL

The	NULL
results	NULL
presented	NULL
here	NULL
support	NULL
the	NULL
possibility	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
by	NULL
Tax	NULL
is	NULL
important	NULL
for	NULL
the	NULL
immortalization	NULL
of	NULL
primary	NULL
T	NULL
lymphocytes	NULL
by	NULL
HTLV-1	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
activation	NULL
of	NULL
the	NULL
CREB/ATF	NULL
pathway	NULL
by	NULL
Tax	NULL
is	NULL
dispensable	NULL
for	NULL
cellular	NULL
immortalization	NULL
.	NULL

Examination	NULL
of	NULL
the	NULL
immortalizing	NULL
phenotypes	NULL
of	NULL
various	NULL
Tax	NULL
point	NULL
mutants	NULL
in	NULL
a	NULL
functional	NULL
molecular	NULL
clone	NULL
of	NULL
HTLV-1	NULL
likely	NULL
mimics	NULL
the	NULL
infection	NULL
of	NULL
primary	NULL
lymphocytes	NULL
in	NULL
vivo	NULL
more	NULL
closely	NULL
than	NULL
other	NULL
cell	NULL
culture	NULL
models	NULL
which	NULL
have	NULL
been	NULL
used	NULL
to	NULL
study	NULL
cellular	NULL
transformation	NULL
by	NULL
HTLV-1	NULL
.	NULL

This	NULL
system	NULL
will	NULL
be	NULL
useful	NULL
for	NULL
the	NULL
determination	NULL
of	NULL
immortalizing	NULL
activity	NULL
of	NULL
additional	NULL
Tax	NULL
mutants	NULL
defective	NULL
for	NULL
other	NULL
activities	NULL
of	NULL
Tax	NULL
which	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
immortalization	NULL
and	NULL
transformation	NULL
of	NULL
infected	NULL
cells	NULL
,	NULL
which	NULL
will	NULL
lead	NULL
to	NULL
a	NULL
more	NULL
complete	NULL
understanding	NULL
of	NULL
Tax	NULL
function	NULL
and	NULL
the	NULL
pathogenesis	NULL
of	NULL
HTLV-1	NULL
infection	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Warner	NULL
C.	NULL
Greene	NULL
for	NULL
the	NULL
gift	NULL
of	NULL
the	NULL
M22	NULL
and	NULL
M47	NULL
Tax	NULL
mutant	NULL
expression	NULL
plasmids	NULL
and	NULL
Cetus	NULL
for	NULL
the	NULL
gift	NULL
of	NULL
IL-2	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Fen-Hwa	NULL
Wong	NULL
for	NULL
construction	NULL
of	NULL
the	NULL
ACH	NULL
Tax	NULL
mutant	NULL
plasmids	NULL
and	NULL
Samuel	NULL
R.	NULL
Trejo	NULL
,	NULL
Toni	NULL
Portis	NULL
,	NULL
and	NULL
Nancy	NULL
Vander-Heyden	NULL
for	NULL
helpful	NULL
discussions	NULL
and	NULL
critical	NULL
reviews	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
PHS	NULL
grant	NULL
CA64317	NULL
and	NULL
training	NULL
grant	NULL
GM07076	NULL
(	NULL
M.D.R	NULL
.	NULL
)	NULL

.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Adya	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
C.-Z	NULL
.	NULL

Giam	NULL
.	NULL

1995	NULL
.	NULL

Distinct	NULL
regions	NULL
in	NULL
human	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
I	NULL
Tax	NULL
mediate	NULL
interactions	NULL
with	NULL
activator	NULL
protein	NULL
CREB	NULL
and	NULL
basal	NULL
transcription	NULL
factors	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:1834-1841	NULL
.	NULL

2	NULL
.	NULL

Akagi	NULL
,	NULL
T.	NULL
,	NULL
H.	NULL
Ono	NULL
,	NULL
H.	NULL
Nyunoya	NULL
,	NULL
and	NULL
K.	NULL
Shimotohno	NULL
.	NULL

1997	NULL
.	NULL

Characterization	NULL
of	NULL
peripheral	NULL
blood	NULL
T-lymphocytes	NULL
transduced	NULL
with	NULL
HTLV-1	NULL
Tax	NULL
mutants	NULL
with	NULL
different	NULL
trans-activating	NULL
phenotypes	NULL
.	NULL

Oncogene	NULL
14:2071-2080	NULL
.	NULL

3	NULL
.	NULL

Ballard	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
E.	NULL
Bohnlein	NULL
,	NULL
J.	NULL
W.	NULL
Lowenthal	NULL
,	NULL
Y.	NULL
Wano	NULL
,	NULL
B.	NULL
R.	NULL
Franza	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1988	NULL
.	NULL

HTLV-1	NULL
tax	NULL
induces	NULL
cellular	NULL
proteins	NULL
that	NULL
activate	NULL
the	NULL
xB	NULL
clement	NULL
in	NULL
the	NULL
IL-2	NULL
receptor	NULL
alpha	NULL
gene	NULL
.	NULL

Science	NULL
241:1652-1655	NULL
.	NULL

4	NULL
.	NULL

Bantignies	NULL
,	NULL
F.	NULL
,	NULL
R.	NULL
Rousset	NULL
,	NULL
C.	NULL
Desbois	NULL
,	NULL
and	NULL
P.	NULL
Jalinot	NULL
.	NULL

1996	NULL
.	NULL

Genetic	NULL
characterization	NULL
of	NULL
transactivation	NULL
of	NULL
the	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
promoter	NULL
:	NULL
binding	NULL
of	NULL
Tax	NULL
to	NULL
Tax-responsive	NULL
element	NULL
1	NULL
is	NULL
mediated	NULL
by	NULL
the	NULL
4864	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

ROBEK	NULL
AND	NULL
RATNER	NULL
cyclic	NULL
AMP-responsive	NULL
members	NULL
of	NULL
the	NULL
CREB/ATF	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:2174-2182.	NULL
.	NULL

Barnhart	NULL
,	NULL
M.	NULL
K.	NULL
,	NULL
L.	NULL
M.	NULL
Connor	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Marriott	NULL
.	NULL

1997	NULL
.	NULL

Function	NULL
of	NULL
the	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
21-base-pair	NULL
repeats	NULL
in	NULL
basal	NULL
transcrip-tion	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

71:337-344.	NULL
.	NULL

Bex	NULL
,	NULL
F.	NULL
,	NULL
M.	NULL
J.	NULL
Yin	NULL
,	NULL
A.	NULL
Burney	NULL
,	NULL
and	NULL
R.	NULL
B.	NULL
Gaynor	NULL
.	NULL

1998	NULL
.	NULL

Differential	NULL
transcrip-	NULL
tional	NULL
activation	NULL
by	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
mutants	NULL
is	NULL
mediated	NULL
by	NULL
distinct	NULL
interactions	NULL
with	NULL
CREB	NULL
binding	NULL
protein	NULL
and	NULL
p300	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18:2392-2405.	NULL
.	NULL

Bodor	NULL
,	NULL
J.	NULL
,	NULL
W.	NULL
Walker	NULL
,	NULL
E.	NULL
Flemington	NULL
,	NULL
A.-L.	NULL
Spetz	NULL
,	NULL
and	NULL
J.	NULL
F.	NULL
Habener	NULL
.	NULL

1995	NULL
.	NULL

Modulation	NULL
of	NULL
Tax	NULL
and	NULL
PKA-mediated	NULL
expression	NULL
of	NULL
HTLV-1	NULL
promoter	NULL
via	NULL
cAMP	NULL
response	NULL
clement	NULL
binding	NULL
and	NULL
modulator	NULL
proteins	NULL
CREB	NULL
and	NULL
CREM	NULL
.	NULL

FEBS	NULL
Lett	NULL
.	NULL

377:413-418.	NULL
.	NULL

Brauweiler	NULL
,	NULL
A.	NULL
,	NULL
P.	NULL
Garl	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
Franklin	NULL
,	NULL
H.	NULL
A.	NULL
Giebler	NULL
,	NULL
and	NULL
J.	NULL
K.	NULL
Nyborg	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
molecular	NULL
mechanism	NULL
for	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
latency	NULL
and	NULL
Tax	NULL
transactivation	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:12814-12822.	NULL
.	NULL

Brauweiler	NULL
,	NULL
A.	NULL
,	NULL
J.	NULL
E.	NULL
Garrus	NULL
,	NULL
J.	NULL
C.	NULL
Reed	NULL
,	NULL
and	NULL
J.	NULL
K.	NULL
Nyborg	NULL
.	NULL

1997	NULL
.	NULL

Repression	NULL
of	NULL
bax	NULL
gene	NULL
expression	NULL
by	NULL
the	NULL
HTLV-1	NULL
Tax	NULL
protein	NULL
:	NULL
implications	NULL
for	NULL
suppression	NULL
of	NULL
apoptosis	NULL
in	NULL
virally	NULL
infected	NULL
cells	NULL
.	NULL

Virology	NULL
231:135-140	NULL
.	NULL

Cann	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
J.	NULL
D.	NULL
Rosenblatt	NULL
,	NULL
W.	NULL
Wachsman	NULL
,	NULL
N.	NULL
P.	NULL
Shab	NULL
,	NULL
and	NULL
I.	NULL
S.	NULL
Y.	NULL
Chen	NULL
.	NULL

1985	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
gene	NULL
responsible	NULL
for	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
transcriptional	NULL
regulation	NULL
.	NULL

Nature	NULL
318:571-574	NULL
.	NULL

Collins	NULL
,	NULL
N.	NULL
D.	NULL
,	NULL
G.	NULL
C.	NULL
Newbound	NULL
,	NULL
L.	NULL
Ratner	NULL
,	NULL
and	NULL
M.	NULL
D.	NULL
Lairmore	NULL
.	NULL

1996	NULL
.	NULL

In	NULL
vitro	NULL
CD4	NULL
lymphocyte	NULL
transformation	NULL
and	NULL
infection	NULL
in	NULL
a	NULL
rabbit	NULL
model	NULL
with	NULL
a	NULL
molecular	NULL
clone	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:7241-7246	NULL
.	NULL

Devergne	NULL
,	NULL
O.	NULL
,	NULL
E.	NULL
Hatzivassilion	NULL
,	NULL
K.	NULL
M.	NULL
Izumi	NULL
,	NULL
K.	NULL
M.	NULL
Kaye	NULL
,	NULL
M.	NULL
F.	NULL
Kleijnen	NULL
,	NULL
E.	NULL
Kieff	NULL
,	NULL
and	NULL
G.	NULL
Mosialos	NULL
.	NULL

1996	NULL
.	NULL

Association	NULL
of	NULL
TRAF1	NULL
,	NULL
TRAF2	NULL
,	NULL
and	NULL
TRAF3	NULL
with	NULL
an	NULL
Epstein-Barr	NULL
virus	NULL
LMP-1	NULL
domain	NULL
important	NULL
for	NULL
B-lymphocyte	NULL
transformation	NULL
:	NULL
role	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:7098-7108	NULL
.	NULL

Felber	NULL
,	NULL
B.	NULL
K.	NULL
,	NULL
H.	NULL
Paskalis	NULL
,	NULL
C.	NULL
Kleinman-Ewing	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
and	NULL
G.	NULL
N.	NULL
Pavlakis	NULL
.	NULL

1985	NULL
.	NULL

The	NULL
pX	NULL
protein	NULL
of	NULL
HTLV-I	NULL
is	NULL
a	NULL
transcriptional	NULL
transactivator	NULL
of	NULL
its	NULL
long	NULL
terminal	NULL
repeats	NULL
.	NULL

Science	NULL
229:675-679	NULL
.	NULL

Fujii	NULL
,	NULL
M.	NULL
,	NULL
H.	NULL
Tsuchiya	NULL
,	NULL
T.	NULL
Chubjo	NULL
,	NULL
T.	NULL
Akizawa	NULL
,	NULL
and	NULL
M.	NULL
Seiki	NULL
.	NULL

1992	NULL
.	NULL

Interaction	NULL
of	NULL
HTLV-1	NULL
Tax1	NULL
with	NULL
p67°	NULL
``	NULL
*	NULL
``	NULL
causes	NULL
the	NULL
aberrant	NULL
induction	NULL
of	NULL
cellular	NULL
immediate	NULL
carly	NULL
genes	NULL
through	NULL
CArG	NULL
boxes	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

6:2066-2076	NULL
.	NULL

Geleziunas	NULL
,	NULL
R.	NULL
,	NULL
S.	NULL
Ferrell	NULL
,	NULL
X.	NULL
Lin	NULL
,	NULL
Y.	NULL
Mu	NULL
,	NULL
E.	NULL
T.	NULL
Cunningham	NULL
,	NULL
Jr.	NULL
,	NULL
M.	NULL
Grant	NULL
,	NULL
M.	NULL
A.	NULL
Connelly	NULL
,	NULL
J.	NULL
E.	NULL
Hambor	NULL
,	NULL
K.	NULL
B.	NULL
Marcu	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1998	NULL
.	NULL

Human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
induction	NULL
of	NULL
NF-B	NULL
involves	NULL
activation	NULL
of	NULL
the	NULL
IxB	NULL
kinase	NULL
a	NULL
(	NULL
IKKa	NULL
)	NULL
and	NULL
IKK	NULL
B	NULL
cellular	NULL
kinases	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18:5157-5165	NULL
.	NULL

Gessain	NULL
,	NULL
A.	NULL
,	NULL
F.	NULL
Barin	NULL
,	NULL
J.-C.	NULL
Vernant	NULL
,	NULL
O.	NULL
Gout	NULL
,	NULL
L.	NULL
Maurs	NULL
,	NULL
A	NULL
.	NULL

Calendar	NULL
,	NULL
and	NULL
G.	NULL
de	NULL
The	NULL
.	NULL

1985	NULL
.	NULL

Antibodies	NULL
to	NULL
human	NULL
T-lymphotropic	NULL
virus	NULL
type	NULL
1	NULL
in	NULL
patients	NULL
with	NULL
tropical	NULL
spastic	NULL
paraparesis	NULL
.	NULL

Lancet	NULL
ii:407-410	NULL
.	NULL

Gr	NULL
R.	NULL
,	NULL
C.	NULL
Dengler	NULL
,	NULL
I.	NULL
Muller-Fleckenstein	NULL
,	NULL
B.	NULL
Fleckenstein	NULL
,	NULL
K.	NULL
McGuire	NULL
,	NULL
M.-C.	NULL
Dokhelar	NULL
,	NULL
J.	NULL
G.	NULL
Sodroski	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
.	NULL

1989	NULL
.	NULL

Transformation	NULL
to	NULL
continuous	NULL
growth	NULL
of	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
by	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
I	NULL
X-region	NULL
genes	NULL
transduced	NULL
by	NULL
a	NULL
herpesvirus	NULL
saimiri	NULL
vector	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:3351-3355	NULL
.	NULL

Hammarskjold	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
and	NULL
M.	NULL
C.	NULL
Simurda	NULL
.	NULL

1992	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
latent	NULL
membrane	NULL
protein	NULL
transactivates	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
through	NULL
induction	NULL
of	NULL
NF-B	NULL
activity	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:6496-6501	NULL
.	NULL

Hansen	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
S.	NULL
E.	NULL
Nielsen	NULL
,	NULL
and	NULL
K.	NULL
Berg	NULL
.	NULL

1989	NULL
.	NULL

Re-examination	NULL
and	NULL
further	NULL
development	NULL
of	NULL
a	NULL
precise	NULL
and	NULL
rapid	NULL
dye	NULL
method	NULL
for	NULL
measuring	NULL
cell	NULL
growth/	NULL
cell	NULL
kill	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

Methods	NULL
119:203-210	NULL
.	NULL

Harrod	NULL
,	NULL
R.	NULL
,	NULL
Y.	NULL
Tang	NULL
,	NULL
C.	NULL
Nicot	NULL
,	NULL
H.	NULL
S.	NULL
Lu	NULL
,	NULL
A.	NULL
Vassilev	NULL
,	NULL
Y.	NULL
Nakatani	NULL
,	NULL
and	NULL
C.	NULL
Z.	NULL
Giam	NULL
.	NULL

1998	NULL
.	NULL

An	NULL
exposed	NULL
KID-like	NULL
domain	NULL
in	NULL
human	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
recruitment	NULL
of	NULL
coactivators	NULL
CBP/p300	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18:5052-5061	NULL
.	NULL

Hattori	NULL
,	NULL
T.	NULL
,	NULL
T.	NULL
Uchiyama	NULL
,	NULL
T.	NULL
Toibana	NULL
,	NULL
K.	NULL
Takatsuki	NULL
,	NULL
and	NULL
H.	NULL
Uchino	NULL
.	NULL

1981	NULL
.	NULL

Surface	NULL
phenotype	NULL
of	NULL
Japanese	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
cells	NULL
characterized	NULL
by	NULL
monoclonal	NULL
antibodies	NULL
.	NULL

Blood	NULL
58:645-647	NULL
.	NULL

Hinuma	NULL
,	NULL
Y.	NULL
,	NULL
K.	NULL
Nagata	NULL
,	NULL
M.	NULL
Hanaoka	NULL
,	NULL
M.	NULL
Nakai	NULL
,	NULL
T.	NULL
Matsumoto	NULL
,	NULL
K.	NULL
Kinoshita	NULL
,	NULL
S.	NULL
Shirakawa	NULL
,	NULL
and	NULL
I.	NULL
Miyoshi	NULL
.	NULL

1981	NULL
.	NULL

Adult	NULL
T-cell	NULL
leukemia	NULL
antigen	NULL
in	NULL
an	NULL
ATL	NULL
cell	NULL
line	NULL
and	NULL
detection	NULL
of	NULL
antibodies	NULL
to	NULL
the	NULL
antigen	NULL
in	NULL
human	NULL
sera	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
78:6476-6480	NULL
.	NULL

Hirai	NULL
,	NULL
H.	NULL
,	NULL
J.	NULL
Fujisawa	NULL
,	NULL
T.	NULL
Suzuki	NULL
,	NULL
K.	NULL
Ueda	NULL
,	NULL
M.	NULL
Muramatsu	NULL
,	NULL
A.	NULL
Tsuboi	NULL
,	NULL
N.	NULL
Arai	NULL
,	NULL
and	NULL
M.	NULL
Yoshida	NULL
.	NULL

1992	NULL
.	NULL

Transcriptional	NULL
activator	NULL
Tax	NULL
of	NULL
HTLV-1	NULL
binds	NULL
to	NULL
the	NULL
NF-xB	NULL
precursor	NULL
p105	NULL
.	NULL

Oncogene	NULL
7:1737-1742	NULL
.	NULL

Hirai	NULL
,	NULL
H.	NULL
,	NULL
T.	NULL
Suzuki	NULL
,	NULL
J.	NULL
Fujisawa	NULL
,	NULL
J.	NULL
Inoue	NULL
,	NULL
and	NULL
M.	NULL
Yoshida	NULL
.	NULL

1994	NULL
.	NULL

Tax	NULL
protein	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
binds	NULL
to	NULL
the	NULL
ankyrin	NULL
motifs	NULL
of	NULL
inhibitory	NULL
factor	NULL
xB	NULL
and	NULL
induces	NULL
nuclear	NULL
translocation	NULL
of	NULL
transcription	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
proteins	NULL
for	NULL
transcriptional	NULL
activation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:3584-3588	NULL
.	NULL

Inoue	NULL
,	NULL
J.	NULL
,	NULL
M.	NULL
Seiki	NULL
,	NULL
T.	NULL
Taniguchi	NULL
,	NULL
S.	NULL
Tsuru	NULL
,	NULL
and	NULL
M.	NULL
Yoshida	NULL
.	NULL

1986	NULL
.	NULL

Induction	NULL
of	NULL
interleukin	NULL
2	NULL
receptor	NULL
gene	NULL
expression	NULL
by	NULL
p40x	NULL
encoded	NULL
by	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

5:2883-2888	NULL
.	NULL

Inoue	NULL
,	NULL
J.	NULL
,	NULL
M.	NULL
Seiki	NULL
,	NULL
and	NULL
M.	NULL
Yoshida	NULL
.	NULL

1986	NULL
.	NULL

The	NULL
second	NULL
pX	NULL
product	NULL
p27X-III	NULL
of	NULL
HTLV-1	NULL
is	NULL
required	NULL
for	NULL
gag	NULL
gene	NULL
expression	NULL
.	NULL

FEBS	NULL
Lett	NULL
.	NULL

209:187-190	NULL
.	NULL

Inoue	NULL
,	NULL
J.	NULL
,	NULL
M.	NULL
Yoshida	NULL
,	NULL
and	NULL
M.	NULL
Seiki	NULL
.	NULL

1987	NULL
.	NULL

Transcriptional	NULL
(	NULL
p40X	NULL
)	NULL
and	NULL
post	NULL
transcriptional	NULL
(	NULL
p27X-III	NULL
)	NULL
regulators	NULL
are	NULL
required	NULL
for	NULL
the	NULL
expression	NULL
and	NULL
28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

J.	NULL
Virou	NULL
.	NULL

replication	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
I.	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
84:3653-3657	NULL
.	NULL

Izumi	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
oncogene	NULL
product	NULL
latent	NULL
membrane	NULL
protein	NULL
1	NULL
engages	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor-associated	NULL
death	NULL
domain	NULL
protein	NULL
to	NULL
mediate	NULL
B	NULL
lymphocyte	NULL
growth	NULL
transformation	NULL
and	NULL
activate	NULL
NF-xB	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94:12592-12597	NULL
.	NULL

Jeang	NULL
,	NULL
K.	NULL
T.	NULL
,	NULL
S.	NULL
G.	NULL
Widen	NULL
,	NULL
O.	NULL
J.	NULL
Semmes	NULL
,	NULL
and	NULL
S.	NULL
H.	NULL
Wilson	NULL
.	NULL

1990	NULL
.	NULL

HTLV-1	NULL
transactivator	NULL
protein	NULL
,	NULL
Tax	NULL
,	NULL
is	NULL
a	NULL
trans-repressor	NULL
of	NULL
the	NULL
human	NULL
B-polymerase	NULL
gene	NULL
.	NULL

Science	NULL
247:1082-1084	NULL
.	NULL

Jin	NULL
,	NULL
D.-Y	NULL
.	NULL

,	NULL
F.	NULL
Spencer	NULL
,	NULL
and	NULL
K.-T.	NULL
Jeang	NULL
.	NULL

1998	NULL
.	NULL

Human	NULL
T	NULL
cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
oncoprotein	NULL
tax	NULL
targets	NULL
the	NULL
human	NULL
mitotic	NULL
checkpoint	NULL
protein	NULL
MAD1	NULL
.	NULL

Cell	NULL
93:81-91	NULL
.	NULL

Kamihira	NULL
,	NULL
S.	NULL
,	NULL
H.	NULL
Sobda	NULL
,	NULL
S.	NULL
Atogami	NULL
,	NULL
K.	NULL
Toriya	NULL
,	NULL
Y.	NULL
Yamada	NULL
,	NULL
K.	NULL
Tsukazaki	NULL
,	NULL
S.	NULL
Momita	NULL
,	NULL
S.	NULL
Ikeda	NULL
,	NULL
M.	NULL
Kusano	NULL
,	NULL
T.	NULL
Amagasaki	NULL
,	NULL
K.-I	NULL
.	NULL

Kinoshita	NULL
,	NULL
and	NULL
M.	NULL
To-monaga	NULL
.	NULL

1992	NULL
.	NULL

Phenotypic	NULL
diversity	NULL
and	NULL
prognosis	NULL
of	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
.	NULL

Leuk	NULL
.	NULL

Res	NULL
.	NULL

16:435-441	NULL
.	NULL

Kanno	NULL
,	NULL
T.	NULL
,	NULL
K.	NULL
Brown	NULL
,	NULL
and	NULL
U.	NULL
Siebenlist	NULL
.	NULL

1995	NULL
.	NULL

Evidence	NULL
in	NULL
support	NULL
of	NULL
a	NULL
role	NULL
for	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
in	NULL
activating	NULL
NF-	NULL
«	NULL
B	NULL
via	NULL
stimulation	NULL
of	NULL
signaling	NULL
pathways	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:11745-11748	NULL
.	NULL

Kikuchi	NULL
,	NULL
M.	NULL
,	NULL
T.	NULL
Mitsui	NULL
,	NULL
M.	NULL
Takeshita	NULL
,	NULL
H.	NULL
Okamura	NULL
,	NULL
H.	NULL
Naitoh	NULL
,	NULL
and	NULL
T.	NULL
Eimoto	NULL
.	NULL

1984	NULL
.	NULL

Virus	NULL
associated	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
(	NULL
ATL	NULL
)	NULL
in	NULL
Japan	NULL
:	NULL
clin-ical	NULL
,	NULL
histological	NULL
,	NULL
and	NULL
immunological	NULL
studies	NULL
.	NULL

Hematol	NULL
.	NULL

Oncol	NULL
.	NULL

4:67-81	NULL
.	NULL

Kimata	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
F.	NULL
H.	NULL
Wong	NULL
,	NULL
J.	NULL
J.	NULL
Wang	NULL
,	NULL
and	NULL
L.	NULL
Ratner	NULL
.	NULL

1994	NULL
.	NULL

Construction	NULL
and	NULL
characterization	NULL
of	NULL
infectious	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
molecular	NULL
clones	NULL
.	NULL

Virology	NULL
204:656-664	NULL
.	NULL

Kingston	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
and	NULL
J.	NULL
Sheen	NULL
.	NULL

1995	NULL
.	NULL

Phase	NULL
extraction	NULL
assay	NULL
for	NULL
CAT	NULL
activity	NULL
,	NULL
p.	NULL
9.7.5-9.7.11	NULL
.	NULL

In	NULL
F.	NULL
M.	NULL
Ausubel	NULL
,	NULL
R.	NULL
Brent	NULL
,	NULL
R.	NULL
E.	NULL
Kingston	NULL
,	NULL
D.	NULL
D.	NULL
Moore	NULL
,	NULL
J.	NULL
G.	NULL
Seidman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Smith	NULL
,	NULL
and	NULL
K.	NULL
Struhl	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Current	NULL
protocols	NULL
in	NULL
molecular	NULL
biology	NULL
.	NULL

John	NULL
Wiley	NULL
&	NULL
Sons	NULL
,	NULL
Inc.	NULL
,	NULL
New	NULL
York	NULL
,	NULL
N.Y.	NULL
Kitajima	NULL
,	NULL
L	NULL
,	NULL
T.	NULL
Shinobara	NULL
,	NULL
J.	NULL
Bilakovics	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

Brown	NULL
,	NULL
X.	NULL
Xu	NULL
,	NULL
and	NULL
M.	NULL
Nerenberg	NULL
.	NULL

1992	NULL
.	NULL

Ablation	NULL
of	NULL
transplanted	NULL
HTLV-1	NULL
Tax-transformed	NULL
tumors	NULL
in	NULL
mice	NULL
by	NULL
antisense	NULL
inhibition	NULL
of	NULL
NF-kB	NULL
.	NULL

Science	NULL
258:1792-1795	NULL
.	NULL

Kwok	NULL
,	NULL
R.	NULL
P.	NULL
S.	NULL
,	NULL
M.	NULL
E.	NULL
Laurance	NULL
,	NULL
J.	NULL
R.	NULL
Lundblad	NULL
,	NULL
P.	NULL
S.	NULL
Goldman	NULL
,	NULL
H.-M.	NULL
Shih	NULL
,	NULL
L.	NULL
M.	NULL
Connor	NULL
,	NULL
S.	NULL
J.	NULL
Marriott	NULL
,	NULL
and	NULL
R.	NULL
H.	NULL
Goodman	NULL
.	NULL

1996	NULL
.	NULL

Control	NULL
of	NULL
cAMP-regulated	NULL
enhancers	NULL
by	NULL
the	NULL
viral	NULL
transactivator	NULL
Tax	NULL
through	NULL
CREB	NULL
and	NULL
the	NULL
co-activator	NULL
CBP	NULL
.	NULL

Nature	NULL
380:642-646	NULL
.	NULL

Langton	NULL
,	NULL
B.	NULL
C.	NULL
,	NULL
M.	NULL
Sliwkowski	NULL
,	NULL
K.	NULL
V.	NULL
Tran	NULL
,	NULL
S.	NULL
Knapp	NULL
,	NULL
E.	NULL
Keitelman	NULL
,	NULL
C.	NULL
Smith	NULL
,	NULL
S.	NULL
Wallingford	NULL
,	NULL
H.-L.	NULL
Liu	NULL
,	NULL
J.	NULL
S.	NULL
Ralston	NULL
,	NULL
J.	NULL
Brandis	NULL
,	NULL
and	NULL
S.	NULL
Coats	NULL
.	NULL

1988	NULL
.	NULL

Development	NULL
and	NULL
characterization	NULL
of	NULL
monoclonal	NULL
antibodies	NULL
to	NULL
the	NULL
HTLV-1	NULL
Tax	NULL
(	NULL
p40X	NULL
)	NULL
protein	NULL
.	NULL

Med	NULL
.	NULL

Virol	NULL
.	NULL

8:295-302	NULL
.	NULL

Lenzmeier	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
H.	NULL
A.	NULL
Giebler	NULL
,	NULL
and	NULL
J.	NULL
K.	NULL
Nyborg	NULL
.	NULL

1998	NULL
.	NULL

Human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
requires	NULL
direct	NULL
access	NULL
to	NULL
DNA	NULL
for	NULL
recruitment	NULL
of	NULL
CREB	NULL
binding	NULL
to	NULL
the	NULL
viral	NULL
promoter	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18:721-731	NULL
.	NULL

Leung	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1988	NULL
.	NULL

HTLV-1	NULL
transactivator	NULL
induces	NULL
interleu-kin-2	NULL
receptor	NULL
expression	NULL
through	NULL
an	NULL
NF-	NULL
«	NULL
B-like	NULL
factor	NULL
.	NULL

Nature	NULL
333:776-778	NULL
.	NULL

Low	NULL
,	NULL
K.	NULL
G.	NULL
,	NULL
L.	NULL
F.	NULL
Doener	NULL
,	NULL
D.	NULL
B.	NULL
Fernando	NULL
,	NULL
J.	NULL
Grossman	NULL
,	NULL
K.-T.	NULL
Jeang	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Comb	NULL
.	NULL

1997	NULL
.	NULL

Human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
releases	NULL
cell	NULL
cycle	NULL
arrest	NULL
induced	NULL
by	NULL
pl6INK4a	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:1956-1962	NULL
.	NULL

Mann	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
M.	NULL
Popovic	NULL
,	NULL
C.	NULL
Murray	NULL
,	NULL
C.	NULL
Neuland	NULL
,	NULL
D.	NULL
M.	NULL
Strong	NULL
,	NULL
P.	NULL
Sarin	NULL
,	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Blattner	NULL
.	NULL

1983	NULL
.	NULL

Cell	NULL
surface	NULL
antigen	NULL
expression	NULL
in	NULL
newborn	NULL
cord	NULL
blood	NULL
lymphocytes	NULL
infected	NULL
with	NULL
HTLV-1	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

131:2021-2024	NULL
.	NULL

Matsumoto	NULL
,	NULL
K.	NULL
,	NULL
H.	NULL
Shibata	NULL
,	NULL
J.-L	NULL
Fujisawa	NULL
,	NULL
H.	NULL
Inoue	NULL
,	NULL
A.	NULL
Hakura	NULL
,	NULL
T.	NULL
Tsuka-hara	NULL
,	NULL
and	NULL
M.	NULL
Fujii	NULL
.	NULL

1997	NULL
.	NULL

Human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
protein	NULL
transforms	NULL
rat	NULL
fibroblasts	NULL
via	NULL
two	NULL
distinct	NULL
pathways	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

71:4445-4451	NULL
.	NULL

McKinsey	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Brockman	NULL
,	NULL
D.	NULL
C.	NULL
Scherer	NULL
,	NULL
S.	NULL
W.	NULL
Al-Murrani	NULL
,	NULL
P.	NULL
L.	NULL
Green	NULL
,	NULL
and	NULL
D.	NULL
W.	NULL
Ballard	NULL
.	NULL

1996	NULL
.	NULL

Inactivation	NULL
of	NULL
IxBB	NULL
by	NULL
the	NULL
Tax	NULL
protein	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
:	NULL
a	NULL
potential	NULL
mechanism	NULL
for	NULL
constitutive	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:2083-2090	NULL
.	NULL

Mercurio	NULL
,	NULL
F.	NULL
,	NULL
H.	NULL
Zhu	NULL
,	NULL
B.	NULL
W.	NULL
Murray	NULL
,	NULL
A.	NULL
Shevchenko	NULL
,	NULL
B.	NULL
L.	NULL
Bennett	NULL
,	NULL
J.	NULL
Li	NULL
,	NULL
D.	NULL
B	NULL
.	NULL

Young	NULL
,	NULL
M.	NULL
Barbosa	NULL
,	NULL
M.	NULL
Mann	NULL
,	NULL
A.	NULL
Manning	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1997	NULL
.	NULL

IKK-1	NULL
and	NULL
IKK-2	NULL
:	NULL
cytokine-activated	NULL
IxB	NULL
kinases	NULL
essential	NULL
for	NULL
NF-kB	NULL
activation	NULL
.	NULL

Science	NULL
278:860-866	NULL
.	NULL

Mulloy	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
T.	NULL
Kislyakova	NULL
,	NULL
A.	NULL
Cereseto	NULL
,	NULL
L.	NULL
Casareto	NULL
,	NULL
A.	NULL
LoMonico	NULL
,	NULL
J.	NULL
Fullen	NULL
,	NULL
M.	NULL
V.	NULL
Lorenzi	NULL
,	NULL
A.	NULL
Cara	NULL
,	NULL
C.	NULL
Nicot	NULL
,	NULL
C.-Z	NULL
.	NULL

Giam	NULL
,	NULL
and	NULL
G.	NULL
Franchini	NULL
.	NULL

1998	NULL
.	NULL

Human	NULL
T-cell	NULL
lymphotropic/leukemia	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
abrogates	NULL
p53-in-duced	NULL
cell	NULL
cycle	NULL
arrest	NULL
and	NULL
apoptosis	NULL
through	NULL
its	NULL
CREB/ATF	NULL
functional	NULL
domain	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

72:8852-8860	NULL
.	NULL

Murakami	NULL
,	NULL
T.	NULL
,	NULL
H.	NULL
Hirai	NULL
,	NULL
T.	NULL
Suzuki	NULL
,	NULL
J.-L	NULL
Fujisawa	NULL
,	NULL
and	NULL
M.	NULL
Yoshida	NULL
.	NULL

1995	NULL
.	NULL

HTLV-1	NULL
Tax	NULL
enhances	NULL
NF-	NULL
«	NULL
B2	NULL
expression	NULL
and	NULL
binds	NULL
to	NULL
the	NULL
products	NULL
p52	NULL
and	NULL
p100	NULL
,	NULL
but	NULL
does	NULL
not	NULL
suppress	NULL
the	NULL
inhibitory	NULL
function	NULL
of	NULL
p100	NULL
.	NULL

Virology	NULL
206:1066-1074	NULL
.	NULL

Neri	NULL
,	NULL
A.	NULL
,	NULL
C.	NULL
C.	NULL
Chang	NULL
,	NULL
L.	NULL
Lombardi	NULL
,	NULL
M.	NULL
Salina	NULL
,	NULL
P.	NULL
Corradini	NULL
,	NULL
A.	NULL
T.	NULL
Maiolo	NULL
,	NULL
R.	NULL
S.	NULL
Chaganti	NULL
,	NULL
and	NULL
R.	NULL
Dalla-Favera	NULL
.	NULL

1991	NULL
.	NULL

B	NULL
cell	NULL
lymphoma-associated	NULL
chromosomal	NULL
translocation	NULL
involves	NULL
candidate	NULL
oncogene	NULL
lyt-10	NULL
,	NULL
homologous	NULL
to	NULL
NF-kB	NULL
,	NULL
a	NULL
rel-related	NULL
polypeptide	NULL
.	NULL

Cell	NULL
67:1075-1087	NULL
.	NULL

Neuvent	NULL
,	NULL
C.	NULL
,	NULL
K.	NULL
G.	NULL
Low	NULL
,	NULL
F.	NULL
Maldarelli	NULL
,	NULL
I.	NULL
Schmitt	NULL
,	NULL
F.	NULL
Majone	NULL
,	NULL
R.	NULL
Gr	NULL
and	NULL
K.	NULL
T.	NULL
Jeang	NULL
.	NULL

1998	NULL
.	NULL

Human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
and	NULL
cell	NULL
cycle	NULL
progression	NULL
:	NULL
role	NULL
of	NULL
cyclin	NULL
D-cdk	NULL
and	NULL
p110Rb	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18:3620-3632	NULL
.	NULL

Newbound	NULL
,	NULL
G.	NULL
C.	NULL
,	NULL
J.	NULL
M.	NULL
Andrews	NULL
,	NULL
J.	NULL
P.	NULL
O'Rourke	NULL
,	NULL
J.	NULL
N.	NULL
Brady	NULL
,	NULL
and	NULL
M.	NULL
D.	NULL
Lairmore	NULL
.	NULL

1996	NULL
.	NULL

Human	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
mediates	NULL
en-	NULL
voL	NULL
.	NULL

73	NULL
,	NULL
1999	NULL
51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

66.	NULL
hanced	NULL
transcription	NULL
in	NULL
CD4*	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:2101-2106	NULL
.	NULL

Ohno	NULL
,	NULL
H.	NULL
,	NULL
G.	NULL
Takimoto	NULL
,	NULL
and	NULL
T.	NULL
W.	NULL
McKeithan	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
candidate	NULL
proto-oncogene	NULL
bel-3	NULL
is	NULL
related	NULL
to	NULL
genes	NULL
implicated	NULL
in	NULL
cell	NULL
lincage	NULL
determination	NULL
and	NULL
cell	NULL
cycle	NULL
control	NULL
.	NULL

Cell	NULL
60:991-997	NULL
.	NULL

Okumura	NULL
,	NULL
K.	NULL
,	NULL
S.	NULL
Tagaki	NULL
,	NULL
G.	NULL
Sakaguchi	NULL
,	NULL
K.	NULL
Naito	NULL
,	NULL
N.	NULL
Minoura-Tada	NULL
,	NULL
H.	NULL
Kobayashi	NULL
,	NULL
T.	NULL
Mimori	NULL
,	NULL
Y.	NULL
Hinuma	NULL
,	NULL
and	NULL
H.	NULL
Igarashi	NULL
.	NULL

1994	NULL
.	NULL

Autoantigen	NULL
Ku	NULL
protein	NULL
is	NULL
involved	NULL
in	NULL
DNA	NULL
binding	NULL
proteins	NULL
which	NULL
recognize	NULL
the	NULL
US	NULL
repressive	NULL
element	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
I	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

FEBS	NULL
Lett	NULL
.	NULL

356:94-100	NULL
.	NULL

Osame	NULL
,	NULL
M.	NULL
,	NULL
K.	NULL
Usuku	NULL
,	NULL
S.	NULL
Zumo	NULL
,	NULL
N.	NULL
Jichi	NULL
,	NULL
H.	NULL
Amitini	NULL
,	NULL
and	NULL
A.	NULL
Igata	NULL
.	NULL

1986	NULL
.	NULL

HTLV-I	NULL
associated	NULL
myelopathy	NULL
:	NULL
a	NULL
new	NULL
clinical	NULL
entity	NULL
.	NULL

Lancet	NULL
i:1031-1032	NULL
.	NULL

(	NULL
Letter	NULL
.	NULL
)	NULL

Persaud	NULL
,	NULL
D.	NULL
,	NULL
J.	NULL
L.	NULL
Munoz	NULL
,	NULL
S.	NULL
L.	NULL
Tarsis	NULL
,	NULL
E.	NULL
S.	NULL
Parks	NULL
,	NULL
and	NULL
W.	NULL
P.	NULL
Parks	NULL
.	NULL

1995	NULL
.	NULL

Time	NULL
course	NULL
and	NULL
cytokine	NULL
dependence	NULL
of	NULL
human	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
1	NULL
T-lymphocyte	NULL
transformation	NULL
as	NULL
revealed	NULL
by	NULL
a	NULL
microtiter	NULL
infectivity	NULL
assay	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:6297-6303	NULL
.	NULL

Pise-Masison	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
K.-S.	NULL
Choi	NULL
,	NULL
M.	NULL
Radonovich	NULL
,	NULL
J.	NULL
Dittmer	NULL
,	NULL
S.-J	NULL
.	NULL

Kim	NULL
,	NULL
and	NULL
J.	NULL
N.	NULL
Brady	NULL
.	NULL

1998	NULL
.	NULL

Inhibition	NULL
of	NULL
p53	NULL
transactivation	NULL
function	NULL
by	NULL
the	NULL
human	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
protein	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

72:1165-1170	NULL
.	NULL

Pise-Masison	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
M.	NULL
Radonovich	NULL
,	NULL
K.	NULL
Sakaguchi	NULL
,	NULL
E.	NULL
Appella	NULL
,	NULL
and	NULL
J.	NULL
H.	NULL
Brady	NULL
.	NULL

1998	NULL
.	NULL

Phosphorylation	NULL
of	NULL
p53	NULL
:	NULL
a	NULL
novel	NULL
pathway	NULL
for	NULL
p53	NULL
inactivation	NULL
in	NULL
human	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
1-transformed	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

72:6348-6355	NULL
.	NULL

Poiesz	NULL
,	NULL
B.	NULL
J.	NULL
,	NULL
F.	NULL
W.	NULL
Ruscetti	NULL
,	NULL
A.	NULL
F.	NULL
Gazdar	NULL
,	NULL
P.	NULL
A.	NULL
Bunn	NULL
,	NULL
J.	NULL
D.	NULL
Minna	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1980	NULL
.	NULL

Detection	NULL
and	NULL
isolation	NULL
of	NULL
type	NULL
C	NULL
retrovirus	NULL
particles	NULL
from	NULL
fresh	NULL
and	NULL
cultured	NULL
lymphocytes	NULL
of	NULL
a	NULL
patient	NULL
with	NULL
cutaneous	NULL
T-cell	NULL
lymphoma	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
77:7415-7419	NULL
.	NULL

Ressler	NULL
,	NULL
S.	NULL
,	NULL
G.	NULL
F.	NULL
Morris	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Marriott	NULL
.	NULL

1997	NULL
.	NULL

Human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
transactivates	NULL
the	NULL
human	NULL
proliferating	NULL
cell	NULL
nuclear	NULL
antigen	NULL
promoter	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

71:1181-1190	NULL
.	NULL

Richardson	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
A.	NULL
J.	NULL
Edwards	NULL
,	NULL
J.	NULL
K.	NULL
Cruikshank	NULL
,	NULL
P.	NULL
Rudge	NULL
,	NULL
and	NULL
A.	NULL
G.	NULL
Dalgleish	NULL
.	NULL

1990	NULL
.	NULL

In	NULL
vivo	NULL
cellular	NULL
tropism	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:5682-5687	NULL
.	NULL

Richardson	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
P.	NULL
Hollsberg	NULL
,	NULL
A.	NULL
Windhagen	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

Child	NULL
,	NULL
D.	NULL
A.	NULL
Hafler	NULL
,	NULL
and	NULL
A.	NULL
M.	NULL
L.	NULL
Lever	NULL
.	NULL

1997	NULL
.	NULL

Variable	NULL
immortalizing	NULL
potential	NULL
and	NULL
frequent	NULL
virus	NULL
latency	NULL
in	NULL
blood-derived	NULL
T-cell	NULL
clones	NULL
infected	NULL
with	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

Blood	NULL
89:3303-3314	NULL
.	NULL

Rimsky	NULL
,	NULL
L.	NULL
,	NULL
J.	NULL
Hauber	NULL
,	NULL
M.	NULL
Dukovich	NULL
,	NULL
M.	NULL
H.	NULL
Malim	NULL
,	NULL
A.	NULL
Langlois	NULL
,	NULL
B.	NULL
R.	NULL
Cullen	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1988	NULL
.	NULL

Functional	NULL
replacement	NULL
of	NULL
the	NULL
HIV-1	NULL
rev	NULL
protein	NULL
by	NULL
the	NULL
HTLV-1	NULL
rex	NULL
protein	NULL
.	NULL

Nature	NULL
335:738-740	NULL
.	NULL

Rosin	NULL
,	NULL
R.	NULL
,	NULL
C.	NULL
Koch	NULL
,	NULL
I.	NULL
Schmitt	NULL
,	NULL
O.	NULL
J.	NULL
Semmes	NULL
,	NULL
K.-T.	NULL
Jeang	NULL
,	NULL
and	NULL
R.	NULL
Grassmann	NULL
.	NULL

1998	NULL
.	NULL

A	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
Tax	NULL
variant	NULL
incapable	NULL
of	NULL
activating	NULL
NF-B	NULL
retains	NULL
its	NULL
immortalizing	NULL
potential	NULL
for	NULL
primary	NULL
T-lymphocytes	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

273:6698-6703	NULL
.	NULL

Ross	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
S.	NULL
M.	NULL
Pettiford	NULL
,	NULL
and	NULL
P.	NULL
L.	NULL
Green	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
tax	NULL
gene	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
2	NULL
is	NULL
essential	NULL
for	NULL
transformation	NULL
of	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:5194-5202	NULL
.	NULL

Rousset	NULL
,	NULL
R.	NULL
,	NULL
C.	NULL
Desbois	NULL
,	NULL
F.	NULL
Bantignies	NULL
,	NULL
and	NULL
P.	NULL
Jalinot	NULL
.	NULL

1996	NULL
.	NULL

Effects	NULL
on	NULL
NF-	NULL
«	NULL
B1/p105	NULL
processing	NULL
of	NULL
the	NULL
interaction	NULL
between	NULL
the	NULL
HTLV-1	NULL
transactivator	NULL
Tax	NULL
and	NULL
the	NULL
proteosome	NULL
.	NULL

Nature	NULL
381:328-331	NULL
.	NULL

Schmitt	NULL
,	NULL
L	NULL
,	NULL
O.	NULL
Rosin	NULL
,	NULL
P.	NULL
Rohwer	NULL
,	NULL
M.	NULL
Gossen	NULL
,	NULL
and	NULL
R.	NULL
Grassmann	NULL
.	NULL

1998	NULL
.	NULL

Stimulation	NULL
of	NULL
cyclin-dependent	NULL
kinase	NULL
activity	NULL
and	NULL
G-	NULL
to	NULL
S-phase	NULL
transition	NULL
in	NULL
human	NULL
lymphocytes	NULL
by	NULL
the	NULL
human	NULL
T-cell	NULL
leukemia/lymphotropic	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
protein	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

72:633-640	NULL
.	NULL

Seiki	NULL
,	NULL
M.	NULL
,	NULL
J.	NULL
Inoue	NULL
,	NULL
T.	NULL
Takeda	NULL
,	NULL
and	NULL
M.	NULL
Yoshida	NULL
.	NULL

1986	NULL
.	NULL

Direct	NULL
evidence	NULL
that	NULL
the	NULL
p40x	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type-1	NULL
is	NULL
a	NULL
trans-activating	NULL
transcriptional	NULL
transactivator	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

5:561-565	NULL
.	NULL

IMMORTALIZATION	NULL
OF	NULL
T	NULL
CELLS	NULL
WITH	NULL
HTLV-1	NULL
Tax	NULL
MUTANTS	NULL
67	NULL
.	NULL

68	NULL
.	NULL

69	NULL
.	NULL

70	NULL
.	NULL

72	NULL
.	NULL

73	NULL
.	NULL

75	NULL
.	NULL

76	NULL
.	NULL

77	NULL
.	NULL

78	NULL
.	NULL

79	NULL
.	NULL

80	NULL
.	NULL

4865	NULL
Semmes	NULL
,	NULL
O.	NULL
J.	NULL
,	NULL
and	NULL
K.-T.	NULL
Jeang	NULL
.	NULL

1992	NULL
.	NULL

Mutational	NULL
analysis	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
:	NULL
regions	NULL
necessary	NULL
for	NULL
function	NULL
determined	NULL
with	NULL
47	NULL
mutant	NULL
proteins	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:7183-7192	NULL
.	NULL

Siekevitz	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Feinberg	NULL
,	NULL
N.	NULL
Holbrook	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1987	NULL
.	NULL

Activation	NULL
of	NULL
interleukin	NULL
2	NULL
and	NULL
interleukin	NULL
2-receptor	NULL
(	NULL
tac	NULL
)	NULL
promoter	NULL
expression	NULL
by	NULL
the	NULL
transactivator	NULL
(	NULL
tat	NULL
)	NULL
gene	NULL
product	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
84:5389-5393	NULL
.	NULL

Smith	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1990	NULL
.	NULL

Identification	NULL
of	NULL
HTLV-1	NULL
tax	NULL
transactivator	NULL
mutants	NULL
exhibiting	NULL
novel	NULL
transcriptional	NULL
phenotypes	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

4:1875-1885	NULL
.	NULL

Smith	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1991	NULL
.	NULL

Type	NULL
1	NULL
human	NULL
T	NULL
cell	NULL
leukemia	NULL
virus	NULL
Tax	NULL
protein	NULL
transforms	NULL
rat	NULL
fibroblasts	NULL
through	NULL
the	NULL
cyclic	NULL
adenosine	NULL
mono-phosphate	NULL
response	NULL
element	NULL
binding	NULL
protein/activating	NULL
transcription	NULL
factor	NULL
pathway	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Investig	NULL
.	NULL

88:1038-1042.	NULL
.	NULL

Suzuki	NULL
,	NULL
T.	NULL
,	NULL
H.	NULL
Hirai	NULL
,	NULL
J.	NULL
Fujisawa	NULL
,	NULL
T.	NULL
Fujita	NULL
,	NULL
and	NULL
M.	NULL
Yoshida	NULL
.	NULL

1993	NULL
.	NULL

A	NULL
trans-	NULL
activator	NULL
Tax	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
binds	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
p50	NULL
and	NULL
serum	NULL
response	NULL
factor	NULL
(	NULL
SRF	NULL
)	NULL
and	NULL
associates	NULL
with	NULL
enhancer	NULL
DNAs	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
and	NULL
CArG	NULL
box	NULL
.	NULL

Oncogene	NULL
8:2391-2397	NULL
.	NULL

Suzuki	NULL
,	NULL
T.	NULL
,	NULL
S.	NULL
Kitao	NULL
,	NULL
H.	NULL
Matsushime	NULL
,	NULL
and	NULL
M.	NULL
Yoshida	NULL
.	NULL

1996	NULL
.	NULL

HTLV-1	NULL
Tax	NULL
protein	NULL
interacts	NULL
with	NULL
cyclin-dependent	NULL
kinase	NULL
inhibitor	NULL
p16INK4a	NULL
and	NULL
counteracts	NULL
its	NULL
inhibitory	NULL
activity	NULL
towards	NULL
cdk4	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

15:1607-1614	NULL
.	NULL

Sylla	NULL
,	NULL
B.	NULL
S.	NULL
,	NULL
S.	NULL
C.	NULL
Hung	NULL
,	NULL
D.	NULL
M.	NULL
Davidson	NULL
,	NULL
E.	NULL
Hatzivassiliou	NULL
,	NULL
N.	NULL
L.	NULL
Malinin	NULL
,	NULL
D.	NULL
Wallach	NULL
,	NULL
T.	NULL
D.	NULL
Gilmore	NULL
,	NULL
E.	NULL
Kieff	NULL
,	NULL
and	NULL
G.	NULL
Mosialos	NULL
.	NULL

1998	NULL
.	NULL

Epstcin-Barr	NULL
virus-transforming	NULL
protein	NULL
latent	NULL
membrane	NULL
protein	NULL
1	NULL
activates	NULL
transcription	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
through	NULL
a	NULL
pathway	NULL
that	NULL
includes	NULL
the	NULL
NF-	NULL
«	NULL
B-inducing	NULL
kinase	NULL
and	NULL
the	NULL
IxB	NULL
kinases	NULL
IKKo	NULL
:	NULL
and	NULL
IKKB	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
95:10106-10111.	NULL
.	NULL

Tie	NULL
,	NULL
F.	NULL
,	NULL
N.	NULL
Adya	NULL
,	NULL
W.	NULL
C.	NULL
Greene	NULL
,	NULL
and	NULL
C.-Z	NULL
.	NULL

Giam	NULL
.	NULL

1996	NULL
.	NULL

Interaction	NULL
of	NULL
the	NULL
human	NULL
T-lymphotropic	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
dimer	NULL
with	NULL
CREB	NULL
and	NULL
the	NULL
viral	NULL
21-base-pair	NULL
repeat	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:8368-8374	NULL
.	NULL

Trejo	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
W.	NULL
E.	NULL
Fahl	NULL
,	NULL
and	NULL
L.	NULL
Ratner	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
Tax	NULL
protein	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
mediates	NULL
the	NULL
transactivation	NULL
of	NULL
the	NULL
c-sis/platelet-derived	NULL
growth	NULL
factor-B	NULL
promoter	NULL
through	NULL
interactions	NULL
with	NULL
the	NULL
zinc	NULL
finger	NULL
transcription	NULL
factors	NULL
Sp1	NULL
and	NULL
NGFI-A/Egr-1	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272:27411-27421	NULL
.	NULL

Uittenbogaard	NULL
,	NULL
M.	NULL
N.	NULL
,	NULL
H.	NULL
A.	NULL
Giebler	NULL
,	NULL
D.	NULL
Reisman	NULL
,	NULL
and	NULL
J.	NULL
K.	NULL
Nyborg	NULL
.	NULL

1995	NULL
.	NULL

Transcriptional	NULL
repression	NULL
of	NULL
p53	NULL
by	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
protein	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:28503-28506	NULL
.	NULL

Xiao	NULL
,	NULL
X.	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

Brown	NULL
,	NULL
I.	NULL
Kitajima	NULL
,	NULL
J.	NULL
Bilakovics	NULL
,	NULL
L.	NULL
W.	NULL
Fey	NULL
,	NULL
and	NULL
M.	NULL
I.	NULL
Nerenberg	NULL
.	NULL

1994	NULL
.	NULL

Transcriptional	NULL
suppression	NULL
of	NULL
the	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
I	NULL
long	NULL
terminal	NULL
repeat	NULL
occurs	NULL
by	NULL
an	NULL
unconventional	NULL
interaction	NULL
of	NULL
a	NULL
CREB	NULL
factor	NULL
with	NULL
the	NULL
R	NULL
region	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:5371-5383	NULL
.	NULL

Yamaoka	NULL
,	NULL
S.	NULL
,	NULL
H.	NULL
Inoue	NULL
,	NULL
M.	NULL
Sakurai	NULL
,	NULL
T.	NULL
Sugiyama	NULL
,	NULL
M.	NULL
Hazama	NULL
,	NULL
T.	NULL
Yamada	NULL
,	NULL
and	NULL
M.	NULL
Hatanaka	NULL
.	NULL

1996	NULL
.	NULL

Constitutive	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
essential	NULL
for	NULL
transformation	NULL
of	NULL
rat	NULL
fibroblasts	NULL
by	NULL
the	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
protein	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

15:873-887	NULL
.	NULL

Yin	NULL
,	NULL
M.~J	NULL
.	NULL

,	NULL
L.	NULL
B.	NULL
Christerson	NULL
,	NULL
Y.	NULL
Yamamoto	NULL
,	NULL
Y.-T.	NULL
Kwak	NULL
,	NULL
S.	NULL
Xu	NULL
,	NULL
F.	NULL
Mercurio	NULL
,	NULL
M.	NULL
Barbosa	NULL
,	NULL
M.	NULL
H.	NULL
Cobb	NULL
,	NULL
and	NULL
R.	NULL
B.	NULL
Gaynor	NULL
.	NULL

1998	NULL
.	NULL

HTLV-1	NULL
Tax	NULL
protein	NULL
binds	NULL
to	NULL
MEKK1	NULL
to	NULL
stimulate	NULL
IxB	NULL
kinase	NULL
activity	NULL
and	NULL
NF-kB	NULL
activation	NULL
.	NULL

Cell	NULL
93:875-884	NULL
.	NULL

Yin	NULL
,	NULL
M.-J	NULL
.	NULL

,	NULL
and	NULL
R.	NULL
B.	NULL
Gaynor	NULL
.	NULL

1996	NULL
.	NULL

Complex	NULL
formation	NULL
between	NULL
CREB	NULL
and	NULL
Tax	NULL
enhances	NULL
the	NULL
binding	NULL
affinity	NULL
of	NULL
CREB	NULL
for	NULL
the	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
21-base-pair	NULL
repeats	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:3156-3168.	NULL
.	NULL

Yin	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
E.	NULL
J.	NULL
Paulssen	NULL
,	NULL
J.-S.	NULL
Seeler	NULL
,	NULL
and	NULL
R.	NULL
B.	NULL
Gaynor	NULL
.	NULL

1995	NULL
.	NULL

Protein	NULL
domains	NULL
involved	NULL
in	NULL
both	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
interactions	NULL
between	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
and	NULL
CREB	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:3420-3432	NULL
.	NULL

